{"id":5034,"date":"2024-09-02T12:21:55","date_gmt":"2024-09-02T10:21:55","guid":{"rendered":"https:\/\/thoraxzentrum-ruhrgebiet.de\/yayinlar-2\/torakal-onkoloji-yayinlari\/"},"modified":"2026-10-21T14:26:40","modified_gmt":"2026-10-21T12:26:40","slug":"torakal-onkoloji-yayinlari","status":"publish","type":"page","link":"https:\/\/thoraxzentrum-ruhrgebiet.de\/tr\/yayinlar-2\/torakal-onkoloji-yayinlari\/","title":{"rendered":"Torakal Onkoloji Yay\u0131nlar\u0131"},"content":{"rendered":"\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-7jn1tg-235198ae4e9700e771b96b417cddcc82\">\n#top .av-special-heading.av-7jn1tg-235198ae4e9700e771b96b417cddcc82{\npadding-bottom:10px;\n}\nbody .av-special-heading.av-7jn1tg-235198ae4e9700e771b96b417cddcc82 .av-special-heading-tag .heading-char{\nfont-size:25px;\n}\n.av-special-heading.av-7jn1tg-235198ae4e9700e771b96b417cddcc82 .av-subheading{\nfont-size:15px;\n}\n<\/style>\n<div  class='av-special-heading av-7jn1tg-235198ae4e9700e771b96b417cddcc82 av-special-heading-h1 blockquote modern-quote  avia-builder-el-0  el_before_av_textblock  avia-builder-el-first '><h1 class='av-special-heading-tag '  itemprop=\"headline\"  >Torakal Onkoloji Yay\u0131nlar\u0131<\/h1><div class=\"special-heading-border\"><div class=\"special-heading-inner-border\"><\/div><\/div><\/div>\n<section  class='av_textblock_section av-5cngzo-571dfc2a1e0011d0c4459db5af4aec58 '   itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/CreativeWork\" ><div class='avia_textblock'  itemprop=\"text\" ><p>Burada torakal onkoloji alan\u0131ndaki yay\u0131nlar\u0131m\u0131z hakk\u0131nda bilgiler bulabilirsiniz<\/p>\n<\/div><\/section>\n<div  class='togglecontainer av-4eu9jo-603240cd3a2a3c6bc6b8deedf6d536c7  avia-builder-el-2  el_after_av_textblock  avia-builder-el-last  toggle_close_all' >\n<section class='av_toggle_section av-30nmys-09c7fc70245c9e031349499cbd24ca56'  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/CreativeWork\" ><div role=\"tablist\" class=\"single_toggle\" data-tags=\"{T\u00fcm\u00fc} \"  ><p id='toggle-toggle-id-1' data-fake-id='#toggle-id-1' class='toggler  activeTitle av-title-above '  itemprop=\"headline\"  role='tab' tabindex='0' aria-controls='toggle-id-1' data-slide-speed=\"200\" data-title=\"Yay\u0131nlar\" data-title-open=\"\" data-aria_collapsed=\"Click to expand: Yay\u0131nlar\" data-aria_expanded=\"Click to collapse: Yay\u0131nlar\">Yay\u0131nlar<span class=\"toggle_icon\"><span class=\"vert_icon\"><\/span><span class=\"hor_icon\"><\/span><\/span><\/p><div id='toggle-id-1' aria-labelledby='toggle-toggle-id-1' role='region' class='toggle_wrap  active_tc av-title-above' style='display:block;' ><div class='toggle_content invers-color '  itemprop=\"text\" ><p><strong>Orijinal \u00c7al\u0131\u015fmalar:<\/strong><br \/>\nOrijinal \u00c7al\u0131\u015fmalar:<\/p>\n<p><strong>2025<\/strong><br \/>\n1) Molasiotis A, Jordan K, Karthaus M, Dranitsaris G, Roeland EJ, Schwartzberg LS, Bonizzoni E, Brozos Vazquez E, Buchler T, Chen Y, Christoph DC, Garc\u00eda Alfonso P, Lu X, Majem M, Mavroudis D, Syrigos K, Tomlins E, Zhou Z, Zimovjanova M, Aapro MS (2025): Personalizing antiemetic prophylaxis for patients at high emetic risk: Results from the MyRisk Trial. Ann Oncol Volume 36 (Supplement): S1489-S1490, 2801O. Avrupa T\u0131bbi Onkoloji Derne\u011fi Y\u0131ll\u0131k Toplant\u0131s\u0131&#8217;nda sunum.<\/p>\n<p>2) Metzenmacher M, Thomas M, Griesinger F, de Wit M, Christoph DC, Gro\u00df-Ophoff-M\u00fcller CS, J\u00e4nicke M, Fleitz A, Zacharias S, Groth A, Ludwig P , Kursar M, Fuchs C, Innig R, Dietze G, Dechow LT, Sebastian M, Eberhardt WE (2025): Combined chemo-immunotherapy versus monoimmunotherapy in advanced high PD-L1 positive NSCLC. Real-world data analyzed with propensity scores technique from the German prospective multicentre registry study (CRISP). Ann Oncol Volume 36 (Supplement): S1171, 2087eP. Avrupa T\u0131bbi Onkoloji Derne\u011fi Y\u0131ll\u0131k Toplant\u0131s\u0131&#8217;nda poster sunumu.<\/p>\n<p>3) Eberhardt WEE, Passlick B, Groeschel A, Christoph DC, Grah C, Hoffknecht P, Ludwig P, Groth A, Lennartz C, Jaenicke M, Spring L, Seese B, Sebastian M, Griesinger F, Stuschke M, Thomas M (2025): Real-world treatment and outcome of patients with stage II-III NSCLC in Germany from 2018-24 (prospective German registry CRISP, AIO-TRK-0315). Ann Oncol Volume 36 (Supplement): S1060, 1841eP. Avrupa T\u0131bbi Onkoloji Derne\u011fi Y\u0131ll\u0131k Toplant\u0131s\u0131&#8217;nda poster sunumu.<\/p>\n<p>4) Planchard D, S\u00e9bastien C, Mascaux C, Auliac J-B, Christoph DC, Bonomi L, Chella A, Carcereny E, Pons Tostivint E, Signorelli D, Beghdad F, Dialla O, Khan S, Popat S (2025): Diagnosis and treatment patterns in adults with metastatic non-small cell lung cancer with BRAF V600E mutation in clinical practice: An international ambispective real-world study (OCTOPUS). J Thorac Oncol Volume 20 Issue 3 (Supplement 1), 87P. D\u00fcnya Akci\u011fer Kanseri Konferans\u0131 2025&#8217;te poster sunumu.<\/p>\n<p>5) Molassiotis A, Jordan K, Karthaus M, Dranitsaris G, Roeland EJ, Schwartzberg L, Stimamiglio V, Alonzi A, Tilola SO, Bonizzoni E, Brozos V\u00e1zquez E, Buchler T, Cheng Y, Christoph DC, Garc\u00eda Alfonso P, Lu X, Majem M, Mavroudis D, Syrigos K, Tomlins E, Zhou Z, Zimovjanov\u00e1 M, Aapro M (2025): Enhancing CINV Prevention: NEPA vs. Standard of Care in Patients with Multiple Emetic Risk Factors Receiving Moderately Emetogenic Chemotherapy (MEC). \u00c7ok Uluslu Destekleyici Kanser Bak\u0131m\u0131 Derne\u011fi (MASCC)\/ Uluslararas\u0131 Oral Onkoloji Derne\u011fi (ISOC) 2025 Y\u0131ll\u0131k Toplant\u0131s\u0131&#8217;nda poster sunumu.<\/p>\n<p>6) Girard N, Bar J, Christoph D, Field J Fietkau R, Garassino MC, Garrido Lopez P, Haakensen VD, Hiltermann JTJN, Kao SC, McDonald F, Mornex F, Moskovitz MT, Peters S, Siva S, Solomon B, Qiao X, Anand S, Chander P, Filippi AR (2025): Real-world 5-year survival outcomes with durvalumab (D) after chemoradiotherapy (CRT) in unresectable, stage III NSCLC (urNSCLC): Final data extraction from PACIFIC-R. J Thorac Oncol Volume 30 Issue 2 (Supplement 1), 190P. Avrupa Akci\u011fer Kanseri Konferans\u0131 2025&#8217;te poster sunumu.<\/p>\n<p>7) Planchard D, Couraud S, Mascaux C, Auliac JB, Christoph DC, Bonomi L, Chella A, Carcereny E, Pons-Tostivint E, Signorelli D, Beghdad F, Dialla O, Khan S, Popat S (2025): Diagnosis and treatment patterns in adults with metastatic non-small cell lung cancer with BRAF V600E mutation in clinical practice: An international ambispective real-world study (OCTOPUS). J Thorac Oncol Volume 30 Issue 2 (Supplement 1), 86P. Avrupa Akci\u011fer Kanseri Konferans\u0131 2025&#8217;te poster sunumu<\/p>\n<p><strong>2024<\/strong><br \/>\n1) Kraus FM, Traut A, Nilius G, Volmerig J, Koziorowski A, St\u00f6ver I, Grabellus F, Stahl M, Christoph DC (2024): Pulmonary adenocarcinoma with enteric differentiation (PAED) without TTF-1 expression is a very rare subtype with limited treatment options and poor prognosis. Oncology bask\u0131da.<\/p>\n<p>2) Ferentinos K, Traut A, Gubelt L, Nilius G, Czyborra PB, Nusch A, Langer W, N\u00fcckel H, Hannig CV, Stahl M, Christoph DC (2024): Effectiveness and Safety of Docetaxel in Combination with Nintedanib or Ramucirumab Following Chemoimmunotherapy in Patients with Metastatic Non-Small-Cell Lung Cancer. J Oncol Res Ther 9: 10232. DOI: 10.29011\/2574-710X.10232.<\/p>\n<p>3) Kraus FM, Traut A, Gubelt L, Nilius G, Volmerig J, Koziorowski, St\u00f6ver I, Grabellus F, Stahl, M, Christoph DC (2024) Comparison of Single Agent Check-Point Inhibitors as First-Line Treatment in NSCLC Patients with High PD-L1-Expression. J Oncol Res Ther 9: 10228.<\/p>\n<p>4) Filippi AR, Bar J, Chouaid C, Christoph DC, Field JK, Fietkau R, Garassino MC, Garrido P, Haakensen VD, Kao S, Markman B, McDonald F, Mornex F, Moskovitz M, Peters S, Sibille A, Siva S, van den Heuvel M, Vercauter P, Anand S, Chander P, Licour M, de Lima AR, Qiao Y, Girard N (2024): Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R. ESMO Open 9(6):103464.<\/p>\n<p>5) Neal J, Pavlakis N, Kim S-W, Goto Y, Lim SM, Mountzios G, Fountzilas E, Mochalova A, Christoph DC, Bearz A, Quantin X, Palmero R, Antic V, Chun E, Edubilli TR, Lin Y-C, Huseni M, Ballinger M, Graupner V, Curran D, Vervaet P, Newsom-Davis T (2024): CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy. J Clin Oncol 42(20):2393-2403.<\/p>\n<p><strong>2023<\/strong><br \/>\n1) Borghaei H, de Marinis F, Dumoulin D, Reynolds C, Theelen WSME, Percent I, Gutierrez Calderon V, Johnson ML, Madroszyk-Flandin A, Garon EB, He H, Planchard D, Reck M, Popat S, Herbst RS, Leal TA, Shazer RL, Yan X, Harrigan R, Peters S; SAPPHIRE Investigators (2023): SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. Ann Oncol 35(1):66-76.<\/p>\n<p>2) Borchert S, Mathilakathu A, Nath A, Wessolly M, Mairinger E, Kreidt D, Steinborn J, Walter RFH, Christoph DC, Kollmeier J, Wohlschlaeger J, Mairinger T, Brcic L, Mairinger FD (2023). Cancer-Associated Fibroblasts Influence Survival in Pleural Mesothelioma: Digital Gene Expression Analysis and Supervised Machine Learning Model. Int J Mol Sci. 24(15):12426.<br \/>\n3) Stahl MK, Ertl SW, Engelmeyer P, Heuer HC, Christoph DC (2023): Impact of Geriatric Assessment on the Tolerability of Combination Chemotherapy in Older Patients with Advanced Cancer: A Matched-Pair Analysis. Oncol Res Treat. 46(3):100-105.<\/p>\n<p><strong>2022<\/strong><br \/>\n1) Girard N, Bar J, Garrido P, Garassino MC, McDonald F, Mornex F, Filippi AR, Smit HJM, Peters S, Field JK, Christoph DC, Sibille A, Fietkau R, Haakensen VD, Chouaid C, Markman B, Hiltermann TJN, Taus A, Sawyer W, Allen A, Chander P, Licour M, Solomon B (2022): Treatment Characteristics and Real-World Progression-Free Survival in Patients with Unresectable Stage III NSCLC who Received Durvalumab After Chemoradiotherapy: Findings from the PACIFIC-R Study. J Thorac Oncol. 18:181-193<\/p>\n<p>2) Zhang Z, Xie S, Cai W, Hong ZN, Yang C, Lin Y, Zhu J, Lin Z, Christoph DC, Bohnenberger H, Kepka L, Brueckl WM, Van Houtte P, Kang M, Lin J (2022): A nomogram to predict the recurrence-free survival and analyze the utility of chemotherapy in stage IB non-small cell lung cancer. Transl Lung Cancer Res. 11(1):75-86.<\/p>\n<p><strong>2021<\/strong><br \/>\n1) Mathilakathu A, Borchert S, Wessolly M, Mairinger E, Beckert H, Steinborn J, Hager T, Christoph DC, Kollmeier J, Wohlschlaeger J, Mairinger T, Schmid KW, Walter RFH, Brcic L, Mairinger FD (2021): Mitogen signal-associated pathways, energy metabolism regulation, and mediation of tumor immunogenicity play essential roles in the cellular response of malignant pleural mesotheliomas to platinum-based treatment: a retrospective study. Transl Lung Cancer Res 10(7):3030-3042.<\/p>\n<p>2) Metzenmacher M, Kopp HG, Griesinger F, Reinmuth N, Sebastian M, Serke M, Waller CF, Thomas M, Eggert J, Schmid-Bindert G, Hoiczyk M, Christoph DC, Kimmich M, Deu\u00df B, Seifert S, Held S, Schuler M, Herold T, Breitenbuecher F, Eberhardt WEE (2021): A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer. Ther Adv Med Oncol. 13:1758835921996506.<\/p>\n<p>3) Zeuschner P, H\u00f6lters S, St\u00f6ckle M, Seliger B, Mueller A, Bachmann HS, Gr\u00fcnwald V, Christoph DC, Stenzl A, Grimm MO, Br\u00fcning F, Goebell PJ, Augustin M, Roos F, Harde J, Benz-R\u00fcd I, Staehler M, Junker K (2021): Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study). Cancers (Basel) 13(11):2594.<br \/>\n4) Brcic L, Mathilakathu A, Walter RFH, Wessolly M, Mairinger E, Beckert H, Kreidt D, Steinborn J, Hager T, Christoph DC, Kollmeier J, Mairinger T, Wohlschlaeger J, Schmid KW, Borchert S, Mairinger FD (2021): Digital Gene Expression Analysis of Epithelioid and Sarcomatoid Mesothelioma Reveals Differences in Immunogenicity. Cancers (Basel) 13(8):1761.<\/p>\n<p>5) Ferdinandus J, Metzenmacher M, Kessler L, Umutlu L, Aigner C, Karl KO, Gr\u00fcnwald V, Eberhardt W, Fendler WP, Herrmann K, Faehling M, Christoph DC (2021): Complete metabolic response in patients with advanced nonsmall cell lung cancer with prolonged response to immune checkpoint inhibitor therapy. J Immunother Cancer 9(3):e002262.<\/p>\n<p>6) Frost N, Christopoulos P, Kauffmann-Guerrero D, Stratmann J, Riedel R, Schaefer M, Alt J, G\u00fctz S, Christoph DC, Laack E, Faehling M, Fischer R, Fenchel K, Haen S, Heukamp L, Schulz C, Griesinger F. (2021): Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program. Ther Adv Med Oncol. 13:1758835920980558.<\/p>\n<p><strong>2020<\/strong><br \/>\n1)Faehling M, Schumann C, Christopoulos P, Hoffknecht P, Alt J, Horn M, Eisenmann S, Schlenska-Lange A, Sch\u00fctt P, Steger F, Br\u00fcckl WM, Christoph DC (2020). Durvalumab after definitive chemoradiotherapy in locally advanced NSCLC: Data of the German EAP. Data Brief 34:106556.<\/p>\n<p>2)Faehling M, Schumann C, Christopoulos P, Hoffknecht P, Alt J, Horn M, Eisenmann S, Schlenska-Lange A, Sch\u00fctt P, Steger F, Br\u00fcckl WM, Christoph DC (2020): Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP). Lung Cancer 150:114-122.<\/p>\n<p>3)Staehler M, St\u00f6ckle M, Christoph DC, Stenzl A, Potthoff K, Grimm MO, Klein D, Harde J, Br\u00fcning F, Goebell PJ, Augustin M, Roos F, Benz-R\u00fcd I, Marschner N, Gr\u00fcnwald V (2020): Everolimus after failure of one prior VEGF-targeted therapy in metastatic renal cell carcinoma: Final results of the MARC-2 trial. Int J Cancer, 148(7):1685-1694.<\/p>\n<p>4)Jia Z, Wang Y, Cao L, Wang Y, Song Y, Yang X, Bing Z, Cao Z, Liu P, Zhang S, Chen Z, Huang M, Yu Y, Han-Zhang H, Song J, Christoph DC, Passaro A, Gridelli C, Hishida T, Liang N, Li S (2020): First-line treatment selection with organoids of an EGFRm + TP53m stage IA1 patient with early metastatic recurrence after radical surgery and follow-up. J Thorac Dis. 12(7):3764-3773.<\/p>\n<p>5)Ferdinandus J, Barbato F, Chodyla M, Fendler WP, Kessler L, Pomykala KL, Metzenmacher M, Krefting F, Hager T, Umutlu L, Herrmann K, Christoph DC (2020): Volumetric PET response assessment outperforms conventional criteria in patients receiving high-dose pembrolizumab for malignant mesothelioma. J Nucl Med., 62(2):191-194.<\/p>\n<p><strong>2019<\/strong><br \/>\n1)Walter RFH, Sydow SR, Berg E, Kollmeier J, Christoph DC, Christoph S, Eberhardt WEE, Mairinger T, Wohlschlaeger J, Schmid KW, Mairinger FD (2019): Bortezomib sensitivity is tissue dependent and high expression of the 20S proteasome precludes good response in malignant pleural mesothelioma. Cancer Manag Res. 11:8711-8720.<\/p>\n<p>2)Krefting F, Basara N, Sch\u00fctte W, Sp\u00e4th-Schwalbed E, Alt J, Thiel S, Kimmich G, Fischer JR, Kurz S, Griesinger F, Christoph DC (2019): Clinical Experience of Immunotherapy Treatment: Efficacy and Toxicity Analysis of the Compassionate Use Program of Nivolumab in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer. J Cancer Res Clin Oncol. 42(5):243-255.<\/p>\n<p>3Walter RFH, Vollbrecht C, Werner R, Borchert S, Schmeller J, Mairinger E, Herold T, Streubel A, Christoph DC\u200e, Mairinger T, Schmid KW, Wohlschl\u00e4ger J, Hager T, Mairinger F (2019): Processing escape mechanisms through altered proteasomal cleavage of epitopes affect immune response in pulmonary neuroendocrine tumors. Technol Cancer Res T, 17: 1533033818818418.<\/p>\n<p>4)Borchert S, Wessolly M, Schmeller J, Mairinger E, Kollmeier J, Hager T, Mairinger T, Herold T, Christoph DC, Walter RFH, Eberhardt WEE, Pl\u00f6nes T, Wohlschlaeger J, Aigner C, Schmid KW, Mairinger FD (2019): Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro. BMC Cancer 19(1):108.<\/p>\n<p><strong>2018<\/strong><br \/>\n1)Stratmann JA, Michels S, Hornetz S, Christoph DC, Sackmann S, Spengler W, Bischoff H, Sch\u00e4fer M, Alt J, M\u00fcller A, Laack E, Kimmich M, Griesinger F, Sebastian M (2018): Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small cell lung cancer. J Cancer Res Clin Oncol. 144(12):2457-2463.<\/p>\n<p>2)Oezkan F, Herold T, Darwiche K, Eberhardt WEE, Worm K, Christoph DC, Wiesweg M, Freitag L, Schmid KW, Theegarten D, Hager T, Koenig MJ, He K, Taube C, Schuler M, Breitenbuecher F. (2018): Rapid and Highly Sensitive Detection of Therapeutically Relevant Oncogenic Driver Mutations in EBUS-TBNA Specimens From Patients With Lung Adenocarcinoma. Clin Lung Cancer. 19(6):e879-e884.<\/p>\n<p>3)Walter RFH, Werner R, Wessolly M, Mairinger E, Borchert S, Schmeller J, Kollmeier J, Mairinger T, Hager T, Bankfalvi A, Christoph DC, Eberhardt WEE, Pl\u00f6nes T, Aigner C, Schmid KW, Wohlschlaeger J, Mairinger FD (2018): Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53. J Oncol. 2018:1986982.<\/p>\n<p>4)Mairinger FD, Schmeller J, Borchert S, Wessolly M, Mairinger E, Kollmeier J, Hager T, Mairinger T, Christoph DC, Walter RFH, Eberhardt WEE, Pl\u00f6nes T, Wohlschlaeger J, Jasani B, Schmid KW, Bankfalvi A (2018): Immunohistochemically detectable metallothionein expression in malignant pleural mesotheliomas is strongly associated with early failure to platin-based chemotherapy. Oncotarget. 9(32):22254-22268.<\/p>\n<p><strong>2017<\/strong><br \/>\n1)Peters S, Gettinger S, Johnson ML, J\u00e4nne PA, Garassino MC, Christoph D, Toh CK, Rizvi NA, Chaft JE, Carcereny Costa E, Patel JD, Chow LQM, Koczywas M, Ho C, Fr\u00fch M, van den Heuvel M, Rothenstein J, Reck M, Paz-Ares L, Shepherd FA, Kurata T, Li Z, Qiu J, Kowanetz M, Mocci S, Shankar G, Sandler A, Felip E (2017): Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). J Clin Oncol. 35(24):2781-2789.<\/p>\n<p>2)Welter S, Arfanis E, Christoph D, Hager T, Roesel C, Aigner C, Weinreich G, Theegarten D (2017): Growth patterns of pulmonary metastases: should we adjust resection techniques to primary histology and size? Eur J Cardiothorac Surg. 52(1):39-46.<\/p>\n<p>3)Mairinger FD, Werner R, Flom E, Schmeller J, Borchert S, Wessolly M, Wohlschlaeger J, Hager T, Mairinger T, Kollmeier J, Christoph DC, Schmid KW, Walter RFH (2017): miRNA regulation is important for DNA damage repair and recognition in malignant pleural mesothelioma. Virchows Arch. 470(6):627-637.<\/p>\n<p>4)Mairinger FD, Vollbrecht C, Flom E, Christoph DC, Schmid KW, Kollmeier J, Popper HH, Mairinger T, Walter RFH (2017): Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesothelioma. Oncotarget. 8(23):37502-37510.<\/p>\n<p>5)Wiesweg M, Eberhardt WE, Reis H, Ting S, Savvidou N, Skiba C, Herold T, Christoph DC, Meiler J, Worm K, Kasper S, Theegarten D, Hense J, Hager T, Darwiche K, Oezkan F, Aigner C, Welter S, K\u00fchl H, Stuschke M, Schmid KW, Schuler M (2017): High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer. J Thorac Oncol. 12 (1):54-64.<\/p>\n<p><strong>2016<\/strong><br \/>\n1)Metzenmacher M &#038; Christoph DC (2016): Efficacy and safety of nivolumab combined with standard therapies for first-line therapy of advanced non-small cell lung cancer. J Thorac Dis. 8 (10), E1254-E1256.<\/p>\n<p>2)Walter RF, Werner R, Vollbrecht C, Hager T, Flom E, Christoph DC, Schmeller J, Schmid KW, Wohlschlaeger J, Mairinger FD (2016): ACTB, CDKN1B, GAPDH, GRB2, RHOA and SDCBP Were Identified as Reference Genes in Neuroendocrine Lung Cancer via the nCounter Technology. PLoS One. 11 (11), e0165181.<\/p>\n<p>3)Walter RF, Vollbrecht C, Werner R, Mairinger T, Schmeller J, Flom E, Wohlschlaeger J, Barbetakis N, Paliouras D, Chatzinikolaou F, Adamidis V, Tsakiridis K, Zarogoulidis P, Trakada G, Christoph DC, Schmid KW, Mairinger FD (2016): Screening of Pleural Mesotheliomas for DNA-damage Repair Players by Digital Gene Expression Analysis Can Enhance Clinical Management of Patients Receiving Platin-Based Chemotherapy. J Cancer 7(13):1915-1925.<\/p>\n<p>4)Walter RF, Mairinger FD, Werner R, Vollbrecht C, Hager T, Schmid KW, Wohlschlaeger J, Christoph DC (2016): Folic-acid metabolism and DNA-repair phenotypes differ between neuroendocrine lung tumors and associate with aggressive subtypes, therapy resistance and outcome. Oncotarget 7(15):20166-79.<\/p>\n<p>5)Walter RF, Vollbrecht C, Werner R, Wohlschlaeger J, Christoph DC, Kurt Werner S, Mairinger FD (2016): microRNAs are differentially regulated between MDM2-positive and negative malignant pleural mesothelioma. Oncotarget. 7(14):18713-18721.<\/p>\n<p>6)Fennell DA, Summers Y, Cadranel J, Benepal T, Christoph DC, Lal R, Das M, Maxwell F, Visseren-Grul C, Ferry D. (2016): Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer. Cancer Treat Rev 44:42-50.<\/p>\n<p><strong>2015<\/strong><br \/>\n7)Vollbrecht C, Werner R, Walter RF, Christoph DC, Heukamp LC, Peifer M, Hirsch B, Burbat L, Mairinger T, Kurt Werner S, Wohlschlaeger J, Mairinger FD (2015): Mutational analysis of pulmonary tumours with neuroendocrine features using targeted massive parallel sequencing: a comparison of a neglected tumour group. Br J Cancer 113(12):1704-1711.<\/p>\n<p>8)Oezkan F, Khan AM, Hager T, Freitag L, Christoph D, Darwiche K (2015): OSNA: A Fast Molecular Test Based on CK19 mRNA Concentration for Assessment of EBUS-TBNA Samples in Lung Cancer Patients. Clin Lung Cancer. 17(3):198-204.<\/p>\n<p>9)Walter RF, Mairinger FD, Werner R, Ting S, Vollbrecht C, Theegarten D, Christoph DC, Zarogoulidis K, Schmid KW, Zarogoulidis P, Wohlschlaeger (2015): SOX4, SOX11 and PAX6 mRNA expression was identified as a (prognostic) marker for the aggressiveness of neuroendocrine tumors of the lung by using next-generation expression analysis (NanoString). J. Future Oncol. 11(7):1027-1036.<\/p>\n<p>10)Reis H, Herold T, Ting S, Worm K, Huber U, Christoph DC, Eberhardt WE, Kostbade K, Kasper S, Stamatis G, Welter S, Darwiche K, Karpf-Wissel R, Theegarten D, Schmid KW, Schuler M, Wiesweg M (2015): HER2 expression and markers of phosphoinositide-3-kinase pathway activation define a favorable subgroup of metastatic pulmonary adenocarcinomas. Lung Cancer 88(1):34-41.<\/p>\n<p>11)Walter RF, Mairinger FD, Ting S, Vollbrecht C, Mairinger T, Theegarten D, Christoph DC, Schmid KW, Wohlschlaeger J (2015): MDM2 is an important prognostic and predictive factor for platin-pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14\/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53. Br J Cancer 112(5):883-890.<\/p>\n<p>12)Walter RF, Werner R, Ting S, Vollbrecht C, Theegarten D, Christoph DC, Schmid KW, Wohlschlaeger J, Mairinger FD (2015): Identification of deregulation of apoptosis and cell cycle in neuroendocrine tumors of the lung via NanoString nCounter expression analysis. Oncotarget. 6(28):24690-24698.<\/p>\n<p><strong>2014<\/strong><br \/>\n1)Mairinger FD, Walter RF, Theegarten D, Hager T, Vollbrecht C, Christoph DC, Worm K, Ting S, Werner R, Stamatis G, Mairinger T, Baba H, Zarogoulidis K, Huang H, Li Q, Tsakiridis K, Zarogoulidis P, Kurt Werner S &#038; Wohlschlaeger J (2014): Gene expression analysis of the 26S proteasome subunit PSMB4 reveals significant upregulation, different expression and association with proliferation in human pulmonary neuroendocrine tumours. J Cancer 5(8):646-654.<\/p>\n<p>2)Darwiche K, \u00d6zkan F, Ting S, Johnen G, Br\u00fcning T, Soltermann A, Huber LC, Christoph DC, Freitag L &#038; Franzen D (2014): Bronkoskopik prosed\u00fcrlere \u00f6zel at\u0131fla akci\u011fer kanserinde tedavi \u00f6ncesi biyobelirte\u00e7lerin rol\u00fc [Role of pretherapeutic biomarkers in lung cancer with special regards to bronchoscopic procedures]. Pneumologie 68 (11), 719-726.<\/p>\n<p>3)Mairinger FD, Walter RF, Werner R, Christoph DC, Ting S, Vollbrecht C, Zarogoulidis K, Huang H, Li Q, Schmid KW, Wohlschlaeger J &#038; Zarogoulidis P (2014): Activation of angiogenesis differs strongly between pulmonary carcinoids and neuroendocrine carinomas and is crucial for carcinoid tumourgenesis. J Cancer 5 (6), 465-471.<\/p>\n<p>4)Mairinger FD, Walter RF, Ting S, Vollbrecht C, Kollmeier J, Griff S, Hager T, Mairinger T, Christoph DC, Theegarten D, Kurt Werner S &#038; Wohlschlaeger J (2014): Mdm2 protein expression is strongly associated with survival in malignant pleural mesothelioma. Future Oncol. 10 (6), 995-1005.<\/p>\n<p>5)Christoph DC, Reyna-Asuncion B, Hassan B, Tran C, Maltzman JD, O\u2019Shannessy DJ, Gauler TC, Wohlschlaeger J, Schuler M, Eberhardt WE &#038; Hirsch FRH (2014). Assessment of Folate Receptor alpha and Epidermal Growth Factor Receptor Expression in Pemetrexed-Treated Non-Small Cell Lung Cancer Patients Clin Lung Cancer 15 (5), 320-330.<\/p>\n<p>6)Mairinger FD, Ting S, Werner R, Walter RF, Hager T, Vollbrecht C, Christoph D, Worm K, Mairinger T, Sheu-Grabellus SY, Theegarten D, Schmid KW &#038; Wohlschlaeger J (2014): Different micro-RNA expression profiles distinguish subtypes of neuroendocrine tumors of the lung: results of a profiling study. Mod Pathol. 27 (12), 1623-1640.<\/p>\n<p>7Nensa F, Stattaus J, Morgan B, Horsfield MA, Soria JC, Besse B, Gounant V, Khalil A, Seng K, Fischer B, Krissel H, Laurent D, Christoph D, Eberhardt WE &#038; Gauler TC (2014): Dynamic contrast-enhanced MRI parameters as biomarkers for the effect of vatalanib in patients with non-small-cell lung cancer. Future Oncol. 10 (5), 823-333.<\/p>\n<p>8)Christoph DC &#038; Eberhardt WE (2014): Systemic treatment of malignant pleural mesothelioma: new agents in clinical trials raise hope of relevant improvements. Curr Opin Oncol. 26 (2), 171-181.<\/p>\n<p><strong>2013<\/strong><br \/>\n1)Eberhardt WEE, Hoiczyk M &#038; Christoph DC (2013): Akci\u011fer kanseri tedavisi. TumorDiagn u Ther. 34 (8), 449-452.<\/p>\n<p>2)Ting S, Mairinger FD, Hager T, Welter S, Eberhardt WE, Wohlschlaeger J, Schmid KW &#038; Christoph DC (2013): ERCC1, MLH1, MSH2, MSH6, and \u03b2III-tubulin: resistance proteins associated with response and outcome to platinum-based chemotherapy. Clin Lung Cancer 14 (5), 558-567.<\/p>\n<p>3)Gauler TC, Christoph DC, Fischer J, Frickhofen N, Huber R, Gonschorek C, Roth K, Giurescu M &#038; Eberhardt WEE (2013): Phase-I study of sagopilone (ZK-EPO) in combination with cisplatin in chemotherapy-naive patients with metastasised small-cell lung cancer. Eur J Cancer 49 (11), 2461-2468.<\/p>\n<p>4)Christoph DC &#038; Reckamp KL (2013): Intraventricular chemotherapy of leptomeningeal carcinomatosis from lung cancer \u2013 a feasible and beneficial treatment option? J Thorac Oncol. 8 (5), 523-524.<\/p>\n<p>5)Welter S, Schwan A, Cheufou D, Darwiche K, Christoph D, Eberhardt W, Weinreich G &#038; Stamatis G. (2013): Midterm changes in quality of life: a prospective evaluation after open pulmonary metastasectomy. Ann Thorac Surg. 95 (3), 1006-1011.<\/p>\n<p>6)Christoph DC, Reyna Asuncion B, Hassan B, Tran C, Maltzman JD, O\u2019Shannessy DJ, Wynes MW, Gauler TC, Wohlschlaeger J, Hoiczyk M, Schuler M, Eberhardt WEE &#038; Hirsch FR (2013): Significance of folate receptor alpha and thymidylate synthase expression in patients with non-small cell lung cancer treated with pemetrexed. J Thorac Oncol, 9 (1), 19-30.<\/p>\n<p><strong>2012<\/strong><br \/>\n7) Christoph DC, Reyna Asuncion B, Mascaux C, Tran C, Lu X, Wynes MW, Gauler TC, Wohlschlaeger J, Theegarten D, Neumann V, Hepp C, Welter S, Stamatis G, Tannapfel A, Schuler M, Eberhardt WEE &#038; Hirsch FR (2012): Folylpoly-glutamate synthetase expression is associated with tumor response and outcome from pemetrexed-based chemotherapy in malignant pleural mesothelioma. J Thorac Oncol. 7 (9), 1440-1448.<\/p>\n<p>8)Christoph DC, Kasper S, Gauler TC, Loesch C, Engelhard M, Theegarten D, Poettgen C, Hepp R, Peglow A, Loewendick H, Welter S, Stamatis G, Hirsch FR, Schuler M, Eberhardt WEE &#038; Wohlschlaeger J (2012): \u03b2V-tubulin expression is associated with outcome following taxane-based chemotherapy in non-small cell lung cancer. Br J Cancer. 107 (5), 823-830.<\/p>\n<p>9)Wynes MW, Konopa K, Singh S, Asuncion BR, Ranger-Moore J, Sternau A, Christoph DC, Dzidziuszko R, Jassem J &#038; Hirsch FR (2012). Thymidylate Synthase protein expression by IHC and gene copy number by SISH correlate and show great variability in non-small cell lung cancer. J Thorac Oncol. 7 (6), 982-992.<\/p>\n<p>10)Christoph DC, Hoffmann, A-C, Gauler TC, Reyna Asuncion B, Loewendick H, Peglow A, Hassan B, Tran C, Wynes MW, Schuler M, Eberhardt WE &#038; Hirsch FR (2012). Detection of circulating lung cancer cells with strong thymidylate synthase reactivity in the peripheral blood of a patient with pulmonary adenocarcinoma treated with pemetrexed. J Thorac Oncol. 7 (4), 766-767.<\/p>\n<p><strong>2011<\/strong><br \/>\n1)Christoph DC &#038; Schuler M (2011). Plk1 inhibitors in mono- and combination therapies: a new strategy for treating malignancies. Expert Rev. Anticancer Ther. 11 (7), 1117-1132.<\/p>\n<p>2)Christoph DC, Witkowski L, Stattaus J, Poettgen C, Keyvani C, Gauler TC, Schuler M &#038; Eberhardt WEE (2011). Very late and isolated leptomeningeal relapse of a pulmonary adenocarcinoma presenting as dementia. Onkologie 34 (6), 316-320.<\/p>\n<p><strong>2009<\/strong><br \/>\n1)Christoph DC, Boese D, Johnson KT, Schlosser TW, Hunold P, Baba HA, Erbel R &#038; Philipp S (2009). Heart failure and cardiac involvement as isolated manifestation of familial form of transthyretin amyloidosis resulting from Val30Met mutation with no clinical signs of polyneuropathy. Circ Heart Fail. 2 (5), 512-515.<\/p>\n<p><strong>2004<\/strong><br \/>\n2)Keiper M, Stope MB, Szatkowski DC, B\u00f6hm A, Tysack K, vom Dorp F, Saur O, Oude Weernink PA, Evellin S, Jakobs KH &#038; Schmidt M. Epac- and Ca2+-controlled activation of Ras and extracellular signal-regulated kinases by Gs-coupled receptors (2004). J Biol Chem. 279 (45), 46497-46508.<\/p>\n<p>3)Stope MB, vom Dorp F, Szatkowski DC, B\u00f6hm A, Keiper M, Nolte J, Oude Weernink PA, Rosskopf D, Evellin S, Jakobs KH &#038; Schmidt M (2004). Rap2B-dependent stimulation of phospholipase C-epsilon by epidermal growth factor receptor mediated by c-Src phosphorylation of RasGRP3. Mol Cell Biol. 24 (11), 4664-4676.<\/p>\n<p><strong>Konferanslardaki \u00f6zetler ve sunumlar:<\/strong><\/p>\n<p><strong>2024<\/strong><br \/>\n1) Shah R, Reck M, Grohe C, Christoph DC, Buchmeier EL, Saalfeld FC, Frost N, Kopp H-G, Faehling M, Griesinger F, Roeper J, Hoffknecht P, Kuon J, Luan J, Chesi P, Christopoulos P, Thomas M (2024): Efficacy of nivolumab\/ipilimumab as first-line treatment of pleural mesothelioma in the German real-world setting. J Clin Oncol 42, 2024 (suppl 16; abstr 8085). Amerikan Klinik Onkoloji Derne\u011fi Y\u0131ll\u0131k Toplant\u0131s\u0131&#8217;nda poster sunumu.<\/p>\n<p>2) Hautzel H, Metzenmacher M, B\u00f6l\u00fckbas S, Volmerig J, Nilius G, Kersting D, Moka D, Herrmann K, Christoph D (2024): Tumorvolumetrische Parameter MTV und TLG zur Pr\u00e4diktion von progressionsfreiem und Gesamt-\u00dcberleben beim nicht-resektablen Malignen Mesotheliom unter Doppelimmuntherapie mit Ipilimumab und Nivolumab: Was kann die baseline FDG PET\/CT leisten? NuclearMedicine 63 (2), V06. Alman N\u00fckleer T\u0131p Derne\u011fi Y\u0131ll\u0131k Toplant\u0131s\u0131&#8217;nda sunum.<\/p>\n<p>3) Christoph D, Metzenmacher M, B\u00f6l\u00fckbas S, Volmerig J, Nilius G, Moka D, Hautzel H (2024): PET-CT detects response to treatment with ipilimumab and nivolumab in malignant mesothelioma better than CT. Oncol Res Treat. Volume 47 (Supplement 1), P756. 36. Alman Kanser Kongresi&#8217;nde poster sunumu.<\/p>\n<p>4) Karthaus M, Christoph D, Lux MP, Hofheinz R-D, Jordan K (2024): Bewertung des Nutzens von NEPA (fixe Kombination von Netupitant\/Palonosetron) zur Vorbeugung von durch Chemotherapie ausgel\u00f6ster \u00dcbelkeit und Erbrechen (CINV) bei Patienten mit erh\u00f6htem Emesisrisiko, die eine moderat emetogene Chemotherapie erhalten. Oncol Res Treat. Volume 47 (Supplement 1), P445. 36. Alman Kanser Kongresi&#8217;nde poster sunumu.<\/p>\n<p>5) Reitnauer L, Evers G, Christoph D, Br\u00fcckl W, Wiesweg M, Glanemann F, Webend\u00f6rfer M, Kropf-Sanchen C, Acker F, Sch\u00fctte W, Hoffknecht P, Kerkhoff A, Mohr M, Lenz G, Frost N, Overbeck T, Sebastian M, Bleckmann A (2024): Recurrence of locally advanced NSCLC after radiochemotherapy and consolidative Durvalumab &#8211; A german multicenter retrospective analysis. Oncol Res Treat. Volume 47 (Supplement 1), P947. 36. Alman Kanser Kongresi&#8217;nde poster sunumu.<\/p>\n<p>6) Ferentinos K, Volmerig J, Nilius G, Jaeger B, Koziorowski A, Stoever I, Christoph DC (2024): Addressing systemic first line therapy of elderly lung cancer patients is critical. Oncol Res Treat. Volume 47 (Supplement 1), P755. 36. Alman Kanser Kongresi&#8217;nde poster sunumu.<\/p>\n<p><strong>2023<\/strong><br \/>\n1) Christoph DCCC, Metzenmacher M, B\u00f6l\u00fckbas S, Volmerig4 J, Nilius G, Moka D, Hautzel H (2023): PET-CT detects response to treatment with ipilimumab and nivolumab in malignant mesothelioma far better than CT. Ann Oncol Volume 34 (Supplement 2): S1135-S1144, 2196P. Avrupa T\u0131bbi Onkoloji Derne\u011fi Y\u0131ll\u0131k Toplant\u0131s\u0131&#8217;nda poster sunumu.<\/p>\n<p>2) Kuon JB, Blasi M, Kokowski K, Faehling4 M, Schuette W, Christoph DCC, Kimmich M, Engel-Riedel W, Fischer JR, Lehmann M, Ulmer M, Schuett P, Moosmann N, Meyer zum B\u00fcschenfelde C, Griesinger F, Schneider M, Behnisch R, Stenzinger A, Christopoulos P, Thomas M (2023): DURATION: A multicenter randomized phase II trial investigating sequential mono- (mCTX) or doublet-chemotherapy (dCTX) followed by durvalumab (D) in older or frail patients with advanced non-small cell lung cancer (NSCLC). Ann Oncol Volume 34 (Supplement 2): S755-S851, 1442P Avrupa T\u0131bbi Onkoloji Derne\u011fi Y\u0131ll\u0131k Toplant\u0131s\u0131&#8217;nda poster sunumu.<\/p>\n<p>3) Ferentinos K, Volmerig J, Nilius G, Jaeger B, Koziorowski A, Stoever I, Christoph DCCC (2023): Challenge of systemic first-line treatment of elderly lung cancer patients. Ann Oncol Volume 34 (Supplement 2): S755-S851, 1483P. Avrupa T\u0131bbi Onkoloji Derne\u011fi Y\u0131ll\u0131k Toplant\u0131s\u0131&#8217;nda poster sunumu.<\/p>\n<p>4) Evers G, Reitnauer LE, Christoph DCCC, Brueckl WM, Wiesweg M, Glanemann F, Webendoerfer M, Kropf C, Acker F, Hund A, Sch\u00fctte W, Hoffknecht P, Kerkhoff A, Mohr M, Lenz G, Frost N, Overbeck TR, Sebastian M, Bleckmann A (2023): Treatment and clinical outcome in recurrent\/refractory locally advanced NSCLC following chemoradiotherapy and consolidative durvalumab. Ann Oncol Volume 34 (Supplement 2): S746-S754, 1300P. Avrupa T\u0131bbi Onkoloji Derne\u011fi Y\u0131ll\u0131k Toplant\u0131s\u0131&#8217;nda poster sunumu.<\/p>\n<p>5) Karthaus M, Christoph DC, Lux MP, Hofheinz RD, Jordan K (2023): Assessing the Benet of NEPA (Fixed Combination of Netupitant\/Palonosetron) for preventing Chemotherapyinduced Nausea and Vomiting (CINV) in patients at increased emetic risk receiving moderately emetogenic chemotherapy. Oncol Res and Treat 2023, Volume 46 (Supplement 5), P724. DGHO, OeGHO ve SGHSSH Y\u0131ll\u0131k Toplant\u0131s\u0131&#8217;nda poster sunumu.<\/p>\n<p>6) Ferentinos K, Volmerig J, Nilius G, Jaeger B, Koziorowski A, Stoever I, Christoph D (2023): Systemic first line treatment of elderly patients with lung cancer: proper choice is difficult. Oncol Res and Treat 2023, Volume 46 (Supplement 5), P453. DGHO, OeGHO ve SGHSSH Y\u0131ll\u0131k Toplant\u0131s\u0131&#8217;nda poster sunumu.<\/p>\n<p>7) Reitnauer L, Evers G, Christoph D, Br\u00fcckl W, Wiesweg M, Glanemann F, Webend\u00f6rfer M, Kropf-Sanchen C, Acker F, Sch\u00fctte W, Hoff\u00acknecht P, Kerkho\u00ac A, Mohr M, Lenz G, Frost N, Overbeck T, Sebastian M, Bleckmann A (2023): Relapse after radiochemotherapy and consolidative Durvalumab in Stage III NSCLC \u2013 a retrospective analysis in a real-world setting. Oncol Res and Treat 2023, Volume 46 (Supplement 5), P451. DGHO, OeGHO ve SGHSSH Y\u0131ll\u0131k Toplant\u0131s\u0131&#8217;nda poster sunumu.<\/p>\n<p>8) Christoph D, Metzenmacher M, B\u00f6l\u00fckbas S, Volmerig J, Nilius G, Moka D, Hautzel H (2023): PET-CT detects response to treatment with ipilimumab and nivolumab in malignant mesothelioma far better than CT. Oncol Res and Treat 2023, Volume 46 (Supplement 5), P446. DGHO, OeGHO ve SGHSSH Y\u0131ll\u0131k Toplant\u0131s\u0131&#8217;nda poster sunumu.<\/p>\n<p>9) Peters S, Christoph DC, Field JK, Fietkau R, Filippi AR, Garassino M, Garrido P, McDonald F, Mornex F, Markman B, Solomon BJ, Anand S, Chander P, Qiao Y, Girard N (2023): Real-World Outcomes with Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFRMutated NSCLC (PACIFIC-R) J Thorac Oncol Volume 18 Issue 11 (Supplement), OA17.03. D\u00fcnya Akci\u011fer Kanseri Konferans\u0131 2023&#8217;te sunum.<\/p>\n<p>10) Neal J, Pavlakis N, Kim S-W, Goto Y, Lim SM, Mountzios G, Fountzilas E, Mochalova A, Christoph DC, Bearz A, Quantin A, Palmero R, Antic V, Chun E, Rao Edubilli T, Lin Y-C, Huseni M, Scheffold C, Vervaet P, Newsom-Davis T (2023): Daha \u00f6nce kontrol noktas\u0131 inhibit\u00f6rleri ve kemoterapi ile tedavi edilmi\u015f metastatik KHDAK (mKHDAK) hastalar\u0131nda atezolizumab (atezo) + kabozantinib (cabo) ile dosetaksel (doc) monoterapisinin kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131\u011f\u0131 Faz III bir \u00e7al\u0131\u015fman\u0131n etkinlik ve g\u00fcvenlik sonu\u00e7lar\u0131: CONTACT-01. Journal of Thoracic Oncology, Cilt 18 Say\u0131 4, S39\u2013S40. European Lung Cancer Conference 2023\u2019te s\u00f6zl\u00fc sunum.<\/p>\n<p><strong>2022<\/strong><br \/>\n1) Girard N, Christoph DCC, Garassino MC, McDonald F, Mornex F, Field JK, Fietkau R, Garrido Lopez P, Haakensen VD, Siva S, Van den Heuvel M, Bar J, Chouaid C, Vercauter P, Chander P, Licour M, Anand S, de Lima ARMD, Filippi ARR (2022): Rezeksiyon yap\u0131lamayan Evre III k\u00fc\u00e7\u00fck h\u00fccreli d\u0131\u015f\u0131 akci\u011fer kanseri (KHDAK) hastalar\u0131nda kemoradyoterapi (KRT) sonras\u0131 durvalumab (D) ile ger\u00e7ek ya\u015fam genel sa\u011fkal\u0131m\u0131 (OS): PACIFIC-R \u00e7al\u0131\u015fmas\u0131ndan ara analiz. Ann Oncol Cilt 16 (Ek 1), O580. European Society of Medical Oncology Immuno-Oncology Congress 2022\u2019de poster sunumu.<\/p>\n<p>2) Galuba J, St\u00f6ver I, Koziorowski A, B\u00f6l\u00fckbas S, Nilius G, Christoph D (2022): Atezolizumab tedavisi alan k\u00fc\u00e7\u00fck h\u00fccreli akci\u011fer kanseri hastalar\u0131nda e\u015fzamanl\u0131 uygulanan radyoterapinin g\u00fcvenli\u011fi ve etkinli\u011fi. Oncol Res Treat. Cilt 45 (Ek 3), P606. 35. Alman Kanser Kongresi\u2019nde poster sunumu.<\/p>\n<p>3) Wessolly M, Mathilakathu A, Mairinger E, Nath A, Beckert H, Kreidt D, Klopp N, Heged\u00fcs B, Steinborn J, Hager T, Walter RFH, Christoph DC, Kollmeier J, Wohlschlaeger J, Mairinger T, Brcic L, Borchert S, Schmid KW, FD Mairinger (2022): Kanserle ili\u015fkili fibroblastlar\u0131n aktivitesiyle ba\u011flant\u0131l\u0131 sinyal yolaklar\u0131, malign plevral mezotelyomada kanser progresyonuna ve t\u00fcm\u00f6r h\u00fccresi motilitesinin artmas\u0131na yol a\u00e7ar. Oncol Res Treat. Cilt 45 (Ek 3), P416. 35. Alman Kanser Kongresi\u2019nde poster sunumu.<\/p>\n<p>4) Kraus F, Nilius G, B\u00f6l\u00fckbas S, St\u00f6ver I, Koziorowski A, Grabellus F, Christoph DC (2022): TTF1 ve Napsin A ekspresyonu olmayan adenokarsinomlu k\u00fc\u00e7\u00fck h\u00fccreli d\u0131\u015f\u0131 akci\u011fer kanseri (KHDAK) hastalar\u0131n\u0131n klinik ve patolojik \u00f6zellikleri ile prognozu. Oncol Res Treat. Cilt 45 (Ek 3), P433. 35. Alman Kanser Kongresi\u2019nde poster sunumu.<\/p>\n<p>5) Christoph D, Girard N, Smit H.J.M, Sibille A, Mcdonald F, Mornex F, Garassino MC, Filippi AR, Peters S, Field JK, Drageset Haakensen V, Bar J, Chouaid C, Bray V, Kao S, Sawyer W, Allen A; Licour M, Garrido P, Fietkau R (2022): PACIFIC-R ger\u00e7ek ya\u015fam \u00e7al\u0131\u015fmas\u0131: Kemoradyoterapi sonras\u0131 durvalumab ile tedavi edilen, rezeksiyon yap\u0131lamayan Evre III KHDAK hastalar\u0131nda tedavi s\u00fcresi ve progresyonsuz sa\u011fkal\u0131m\u0131n ara analizi. Oncol Res Treat. Cilt 45 (Ek 3), P256. 35. Alman Kanser Kongresi\u2019nde poster sunumu.<\/p>\n<p>6) Gr\u00f6schel A, Passlick B, Stuschke M., Christopoulos P, Reck M, Grah C, Groth A, Hipper A, Chiabudini M, Fleitz A, J\u00e4nicke M, Spring L, Christoph D, Bernhardt C, Reiser M, M.-O. Zahn M-O, Sebastian M, Griesinger F, Thomas M, Eberhardt W (2022): Molek\u00fcler testleme, tedavi ve sonu\u00e7lar\u0131 ara\u015ft\u0131rmaya y\u00f6nelik Klinik Ara\u015ft\u0131rma platformu (CRISP): Almanya\u2019da Evre II ve III KHDAK i\u00e7in ilk ger\u00e7ek ya\u015fam kan\u0131tlar\u0131 \u2013 AIO-TRK-0315. Oncol Res Treat. Cilt 45 (Ek 3), P135. 35. Alman Kanser Kongresi\u2019nde poster sunumu.<\/p>\n<p>7) Zeuschner P, H\u00f6lters S, St\u00f6ckle M, Seliger B, M\u00fcller A, Bachmann HS, Gr\u00fcnwald V, Christoph DC, Stenzl A, Grimm M-O, Br\u00fcning F, Goebell PJ, Augustin M, Roos F, Harde J, Benz-R\u00fcd I, St\u00e4hler M, Junker K (2022): Trombospondin-2 ve LDH: VEGF hedefli bir tedaviden sonra everolimus ile metastatik renal h\u00fccreli karsinom tedavisi i\u00e7in potansiyel prediktif biyobelirte\u00e7ler (MARC-2 \u00e7al\u0131\u015fmas\u0131). Oncol Res Treat. Cilt 45 (Ek 3), P128. 35. Alman Kanser Kongresi\u2019nde poster sunumu.<\/p>\n<p>8) Eberhardt W, Passlick B, Stuschke M, Gr\u00f6schel A, Christopoulos P, Reck M, Ludwig P, Hipper A, Chiabudini M, Spring L, J\u00e4nicke M, Andres-Pons A, Christoph DC, Bernhardt C, Reiser M, Sebastian M, Griesinger F, Thomas M (2022): V899 Akci\u011fer kanseri hastalar\u0131nda molek\u00fcler testleme, tedavi ve hastal\u0131k seyrini ara\u015ft\u0131rmaya y\u00f6nelik klinik platform (CRISP): Almanya\u2019da radyokemoterapi ile tedavi edilen KHDAK hastalar\u0131na ili\u015fkin ger\u00e7ek ya\u015fam kan\u0131tlar\u0131 \u2013 AIO-TRK-0315. Oncol Res Treat. Cilt 45 (Ek 2), V899. DGHO, OeGHO ve SGHSSH y\u0131ll\u0131k toplant\u0131s\u0131nda s\u00f6zl\u00fc sunum.<\/p>\n<p>9) Sebastian M, Reck M, Fischer R, Christoph DC, Bernhardt C, von der Heyde E, Nusch A, Ludwig P, Hipper A, Hanselmann J, Medinger T, Binninger A, J\u00e4nicke M, Christopoulos P, Elender C, Bethge A, Seese B, Gauler T, Waller CF (2022): P327 Almanya\u2019da KHAK hastalar\u0131na ait ilk ger\u00e7ek ya\u015fam sonu\u00e7 verileri \u2013 Clinical Research platform Into molecular testing, treatment and outcome of (non-)Small cell lung carcinoma Patients (CRISP; AIO-TRK-0315) verileri. Oncol Res Treat. Cilt 45 (Ek 2), P327. DGHO, OeGHO ve SGHSSH y\u0131ll\u0131k toplant\u0131s\u0131nda poster sunumu.<\/p>\n<p>10) Passlick B, Stuschke M, Gr\u00f6schel A, Christopoulos P, Reck M, Grah C, Hoffknecht P, Ludwig P, Hipper A, Chiabudini M, Spring L, J\u00e4nicke M, Andres-Pons A, Christoph DC, Bernhardt C, Reiser M, Nusch A, Sebastian M, Griesinger F, Thomas M, Eberhardt W (2022): Molek\u00fcler testleme, tedavi ve sonu\u00e7lar\u0131 ara\u015ft\u0131rmaya y\u00f6nelik Klinik Ara\u015ft\u0131rma platformu (CRISP): Almanya\u2019da Evre I, II ve III KHDAK\u2019a ili\u015fkin ger\u00e7ek ya\u015fam kan\u0131tlar\u0131 \u2013 AIO-TRK-0315. Zentralblatt f\u00fcr Chirurgie 147 (S01). V-130. DGT y\u0131ll\u0131k toplant\u0131s\u0131nda s\u00f6zl\u00fc sunum.<\/p>\n<p>11) Sebastian M, Reck M, Fischer RN, Christoph DC, Bernhardt C, von der Heyde E, Nusch A, Ludwig P, Hipper A, Hanselmann J, Medinger T, Binninger A, J\u00e4nicke M, Christopoulos P, Elender C, Bethge A, Seese B, Gauler TC, Waller C (2022). Almanya\u2019da KHAK i\u00e7in ilk ger\u00e7ek ya\u015fam sonu\u00e7 verileri: Clinical Research platform Into molecular testing, treatment and outcome of (non-)Small cell lung carcinoma Patients (CRISP; AIO-TRK-0315) verileri. Ann Oncol. 33 (S7), P1542. European Society of Medical Oncology y\u0131ll\u0131k toplant\u0131s\u0131nda poster sunumu.<\/p>\n<p>12) Kuon JB, Blasi M, Kokowsk K, Faehling M, Schuette W, Christoph DC, Kimmich M, Engel-Riedel W, Fischer J, Lehmann M, Ulmer M, Schuett P, Moosmann N, Meyer zum Bueschenfelde C, Griesinger F, Schneider M, Behnisch R, Stenzinger A, Christopoulos P, Thomas M (2022): DURATION \u2013 ileri evre KHDAK\u2019l\u0131 ya\u015fl\u0131 \/ k\u0131r\u0131lgan hastalarda (pts) kemoterapiyi (CTX, 4 k\u00fcr) CTX (2 k\u00fcr) ve ard\u0131ndan durvalumab (D) ile kar\u015f\u0131la\u015ft\u0131ran Faz II randomize \u00e7al\u0131\u015fma: Erken etkinlik sonlan\u0131m noktalar\u0131na ili\u015fkin \u00fcst d\u00fczey sonu\u00e7lar. Ann Oncol. 33 (S7), P1021. European Society of Medical Oncology y\u0131ll\u0131k toplant\u0131s\u0131nda poster sunumu.<\/p>\n<p>13) Eberhardt WEE, Passlick B Stuschke M, Groeschel A, Christopoulos P Reck M, Ludwig P, Hipper A, Chiabudini M, Spring L, J\u00e4nicke M, Andres-Pons A, Christoph DC, Bernhardt C, Reiser M, Sebastian M, Griesinger F, Thomas M (2022): Molek\u00fcler testleme, tedavi ve sonu\u00e7lar\u0131 ara\u015ft\u0131rmaya y\u00f6nelik Klinik ara\u015ft\u0131rma platformu (CRISP): Almanya\u2019da radyokemoterapi ile tedavi edilen KHDAK hastalar\u0131na ili\u015fkin ger\u00e7ek ya\u015fam kan\u0131tlar\u0131 \u2013 AIO-TRK-0315. Ann Oncol. 33 (S7), P963. European Society of Medical Oncology y\u0131ll\u0131k toplant\u0131s\u0131nda poster sunumu.<\/p>\n<p>14) Stuschke M, Eberhardt W, Passlick B, Groeschel A, Christopoulos P, Reck M, Grah C, Hoffknecht P, Ludwig P, Hipper A, Chiabudini M, Spring L, Jaenicke M, Andres-Pons A, Christoph DC, Bernhardt C, Reiser M, Nusch A, Sebastian M, Griesinger F, Thomas M (2022): EP05.01-030 CRISP: Almanya\u2019da Evre I, II ve III KHDAK i\u00e7in ilk ger\u00e7ek ya\u015fam kan\u0131tlar\u0131 \u2013 AIO-TRK-0315. J Thorac Oncol. Cilt 17, Say\u0131 9, Ek. EP05.01. World Conference on Lung Cancer 2022\u2019de poster sunumu.<\/p>\n<p><strong>2021<\/strong><br \/>\n1) Kuon J, Blasi M, Kokowski K, Faehling M, Sch\u00fctte W, Christoph DC, Kimmich M, Engel-Riedel W, Fischer JR, Lehmann M, Ulmer M, Schuett P, Moosmann N, Meyer zum B\u00fcschenfelde C, Griesinger F, Fischer von Weikersthal L, Schmidt B, Gleiber W, Kirchen H, Werke M, R\u00fcckert A, Fr\u00f6hling K-P, Schmidtke-Schrezenmeier G, Moulin J-C, Denzlinger C, B\u00f6sche M, Groh\u00e9 C, Bernhard H, Maintz C, Heinrich K, Kern J, Schneider MA, Krisam J, Sternsinger A, Thomas M (2021): Evre IV k\u00fc\u00e7\u00fck h\u00fccreli d\u0131\u015f\u0131 akci\u011fer kanserinde k\u0131r\u0131lgan ve ileri ya\u015f hastalarda durvalumab: randomize Faz II DURATION \u00e7al\u0131\u015fmas\u0131. J Cancer Res Clin Oncol. Cilt 44 (Ek 2), ep641. DGHO, OeGHO ve SGHSSH y\u0131ll\u0131k toplant\u0131s\u0131nda poster sunumu.<\/p>\n<p>2) Galuba JM, Imke S, Koziorowski A, B\u00f6l\u00fckbas S, Nilius G, Christoph DC (2021): Atezolizumab tedavisi alan k\u00fc\u00e7\u00fck h\u00fccreli akci\u011fer kanseri hastalar\u0131nda e\u015fzamanl\u0131 uygulanan radyoterapinin etkinli\u011fi ve g\u00fcvenli\u011fi. Oncol Res Treat. Cilt 44 (Ek 2), ep577. DGHO, OeGHO ve SGHSSH y\u0131ll\u0131k toplant\u0131s\u0131nda poster sunumu.<\/p>\n<p>3) Kraus F, Nilius G, B\u00f6l\u00fckbas S, St\u00f6ver I, Koziorowski A, Grabellus F, Christoph D (2021): TTF1 ve Napsin A ekspresyonu olmayan adenokarsinomlu k\u00fc\u00e7\u00fck h\u00fccreli d\u0131\u015f\u0131 akci\u011fer kanseri (KHDAK) hastalar\u0131n\u0131n klinik ve patolojik \u00f6zellikleri ile prognozu. Oncol Res Treat. Cilt 44 (Ek 2), ep573. DGHO, OeGHO ve SGHSSH y\u0131ll\u0131k toplant\u0131s\u0131nda poster sunumu.<\/p>\n<p>4) Shah R, Klotz LV, Christoph DC, Ried M, Wehler T, Reck M, Wesseler C, Bethge A, de Wit M, Hoffknecht P, J\u00fcrgens J, Kopp H-G, Hackanson B, Waller CF, Reinmuth N, Schneider MA, Krisam J, Christopoulos P, Eichhorn ME, Thomas M (2021): Cerrahi sonras\u0131 plevral mezotelyomada nivolumab ile kemoterapi \u2013 NICITA. Oncol Res Treat. Cilt 44 (Ek 2), ep253. DGHO, OeGHO ve SGHSSH y\u0131ll\u0131k toplant\u0131s\u0131nda poster sunumu.<\/p>\n<p>5) Christoph DC, Girard N, Smit HJM, Sibille A, McDonald F, Mornex F, Garassino MC, Filippi AR, Peters S, Field JK, Drageset Haakensen V, Bar J, Chouaid C, Bray V, Kao S, Sawyer W, Allen A, Licour M, Garrido P, Fietkau R (2021): PACIFIC-R ger\u00e7ek ya\u015fam \u00e7al\u0131\u015fmas\u0131: Kemoradyoterapi sonras\u0131 durvalumab ile tedavi edilen, rezeksiyon yap\u0131lamayan Evre III KHDAK hastalar\u0131nda tedavi s\u00fcresi ve progresyonsuz sa\u011fkal\u0131m\u0131n ara analizi. Oncol Res Treat. Cilt 44 (Ek 2), V495. DGHO, OeGHO ve SGHSSH y\u0131ll\u0131k toplant\u0131s\u0131nda s\u00f6zl\u00fc sunum.<\/p>\n<p>6) Eberhardt WEE, Passlick B, Stuschke M, Gr\u00f6schel A, Christopoulos P, Reck M, Grah C, Groth A, Hipper A, Chiabudini M, Fleitz A, J\u00e4nicke M, Spring L, Christoph DC, Bernhardt C, Reiser M, Zahn M-O, Sebastian M, Griesinger F, Thomas M, CRISP Registry Group (2021): Molek\u00fcler testleme, tedavi ve sonu\u00e7lar\u0131 ara\u015ft\u0131rmaya y\u00f6nelik Klinik ara\u015ft\u0131rma platformu (CRISP): Almanya\u2019da Evre II ve III KHDAK i\u00e7in ilk ger\u00e7ek ya\u015fam kan\u0131tlar\u0131 \u2013 AIO-TRK-0315. J Cancer Res Clin Oncol. Cilt 44 (Ek 2), V288. DGHO, OeGHO ve SGHSSH y\u0131ll\u0131k toplant\u0131s\u0131nda s\u00f6zl\u00fc sunum.<\/p>\n<p>7) Passlick B, Stuschke M, Gr\u00f6schel A, Christopoulos P, Reck M, Grah C, Groth A, Hipper A, Chiabudini M, Fleitz A, J\u00e4nicke M, Spring L, Christoph D, Bernhardt C, Reiser M, Zahn M-O, Sebastian M, Griesinger F, Thomas M, Eberhardt W (2021): Molek\u00fcler testleme, tedavi ve sonu\u00e7lar\u0131 ara\u015ft\u0131rmaya y\u00f6nelik Klinik Ara\u015ft\u0131rma platformu (CRISP): Almanya\u2019da Evre II ve III KHDAK i\u00e7in ilk ger\u00e7ek ya\u015fam kan\u0131tlar\u0131 \u2013 AIO-TRK-0315. Zentralblatt f\u00fcr Chirurgie 146 (S01). V-122. DGT y\u0131ll\u0131k toplant\u0131s\u0131nda s\u00f6zl\u00fc sunum.<\/p>\n<p>8) Kraus F, Nilius G, B\u00f6l\u00fckbas S, St\u00f6ver I, Koziorowski A, Grabellus F, Christoph DC (2021): TTF1 ve Napsin A ekspresyonu olmayan adenokarsinomlu k\u00fc\u00e7\u00fck h\u00fccreli d\u0131\u015f\u0131 akci\u011fer kanseri (KHDAK) hastalar\u0131n\u0131n klinik ve patolojik \u00f6zellikleri ile prognozu. Ann Oncol. 32 (S5), P1812. European Society of Medical Oncology y\u0131ll\u0131k toplant\u0131s\u0131nda poster sunumu.<\/p>\n<p>9) Galuba JM, St\u00f6ver I, Koziorowski A, B\u00f6l\u00fckbas S, Nilius G, Christoph DC (2021): Atezolizumab tedavisi alan k\u00fc\u00e7\u00fck h\u00fccreli akci\u011fer kanseri hastalar\u0131nda e\u015fzamanl\u0131 uygulanan radyoterapinin g\u00fcvenli\u011fi. Ann Oncol. 32 (S5), P1652. European Society of Medical Oncology y\u0131ll\u0131k toplant\u0131s\u0131nda poster sunumu.<\/p>\n<p>10) Gr\u00f6schel A, Passlick B, Stuschke M, Christopoulos P, Reck M, Grah C, Groth A, Hipper A, Chiabudini M, Fleitz A, J\u00e4nicke M, Spring L, Christoph DC, Bernhardt C, Reiser M, Zahn M-O, Sebastian M, Griesinger F, Thomas M, Eberhardt WEE (2021): Molek\u00fcler testleme, tedavi ve sonu\u00e7lar\u0131 ara\u015ft\u0131rmaya y\u00f6nelik Klinik ara\u015ft\u0131rma platformu (CRISP): Almanya\u2019da Evre II ve III KHDAK i\u00e7in ilk ger\u00e7ek ya\u015fam kan\u0131tlar\u0131 \u2013 AIO-TRK-0315. Ann Oncol. 32 (S5), P1162. European Society of Medical Oncology y\u0131ll\u0131k toplant\u0131s\u0131nda poster sunumu.<\/p>\n<p>11) Girard N, Smit HJM, Sibille A, McDonald F, Mornex F, Garassino MCC, Filippi AR, Peters S, Field JK, Christoph DC, Fietkau R, Haakensen VD, Bar J, Chouaid C, Bray V, Kao S, Sawyer W, Allen A, Licour M, Garrido P (2021): PACIFIC-R ger\u00e7ek ya\u015fam \u00e7al\u0131\u015fmas\u0131: Kemoradyoterapi sonras\u0131 durvalumab ile tedavi edilen, rezeksiyon yap\u0131lamayan Evre III KHDAK hastalar\u0131nda tedavi s\u00fcresi ve progresyonsuz sa\u011fkal\u0131m\u0131n ara analizi. Ann Oncol. 32 (S5), MO1171. European Society of Medical Oncology y\u0131ll\u0131k toplant\u0131s\u0131nda mini s\u00f6zl\u00fc sunum.<\/p>\n<p>12) Galuba J, St\u00f6ver I, Koziorowski A, B\u00f6l\u00fckbas S, Nilius G, Christoph D (2021): Atezolizumab tedavisi alan k\u00fc\u00e7\u00fck h\u00fccreli akci\u011fer kanseri hastalar\u0131nda e\u015fzamanl\u0131 uygulanan radyoterapinin g\u00fcvenli\u011fi. J Thorac Oncol. Cilt 16, Say\u0131 10, Ek 1. P63.10. World Conference on Lung Cancer 2021\u2019de poster sunumu.<\/p>\n<p>13) Kraus F, Nilius G, B\u00f6l\u00fckbas S, St\u00f6ver I, Koziorowski A, Grabellus F, Christoph D (2021): TTF-1 ve Napsin A ekspresyonu olmayan enterik adenokarsinomlu KHDAK hastalar\u0131nda patolojik \u00f6zellikler ve prognoz. J Thorac Oncol. Cilt 16, Say\u0131 10, Ek 1. P56.04. World Conference on Lung Cancer 2021\u2019de poster sunumu.<\/p>\n<p>14) Stuschke M, Passlick B, Gr\u00f6schel A, Christopoulos P, Reck M, Grah C, Groth A, Hipper A, Chiabudini M, Fleitz A, J\u00e4nicke M, Spring L, Christoph DC, Bernhardt C, Reiser M, Zahn M-O, Sebastian M, Griesinger F, Thomas M, Eberhardt WE (2021): Akci\u011fer kanseri hastalar\u0131nda molek\u00fcler testleme, tedavi ve hastal\u0131k seyrini ara\u015ft\u0131rmaya y\u00f6nelik klinik platform (CRISP): Almanya\u2019da Evre II ve III KHDAK i\u00e7in ilk ger\u00e7ek ya\u015fam kan\u0131tlar\u0131 \u2013 AIO-TRK-0315 (#175). Strahlentherapie und Onkologie Cilt 197, ek say\u0131 1. VS01-2. DEGRO y\u0131ll\u0131k toplant\u0131s\u0131nda s\u00f6zl\u00fc sunum.<\/p>\n<p>15) Christoph DC, Ferdinandus J, Metzenmacher M, Kessler P, Umutlu L, Aigner C, Kambartel K-O, Gr\u00fcnwald V, Eberhardt WEE, Fendler WP, Herrmann K, Faehling M (2021). \u0130mm\u00fcn kontrol noktas\u0131 inhibit\u00f6r\u00fc tedavisine uzun s\u00fcreli yan\u0131t veren ileri evre k\u00fc\u00e7\u00fck h\u00fccreli d\u0131\u015f\u0131 akci\u011fer kanseri hastalar\u0131nda tam metabolik yan\u0131t. Journal of Clinical Oncology 39:15 (ek) 9050-9050. American Society of Clinical Oncology y\u0131ll\u0131k toplant\u0131s\u0131nda poster tart\u0131\u015fmas\u0131.<\/p>\n<p>16) McDonald F, Mornex F, Garassino MC, Filippi AR, Christoph D, Haakensen VD, Agbarya A, Van den Heuvel M, Vercauter P, Chouaid C, Pichon E, Siva S, Steinbusch L, Peretz I, Solomon B, Decoster L, Sawyer W, Allen A, Licour M, Girard N (2021): PACIFIC-R: Kemoradyoterapi sonras\u0131 durvalumab ile tedavi edilen, rezeksiyon yap\u0131lamayan Evre III KHDAK hastalar\u0131n\u0131n ger\u00e7ek ya\u015fam \u00f6zellikleri. J Thorac Oncol. Cilt 16, Say\u0131 4, Ek 1. MO79. European Lung Cancer Conference 2021\u2019de mini s\u00f6zl\u00fc sunum.<\/p>\n<p><strong>2020<\/strong><br \/>\n1) Shah R, Klotz LV, Fei\u00dft M, Schneider M, Kriegsmann M, Ried M, Wesseler C, Christoph DC, de Wit M, J\u00fcrgens J, Kopp H-G, Wehler T, Reck M, Sackmann S, Waller C, Reinmuth N, Bischoff H, Winter H, Eichhorn M, Thomas M (2020): NICITA: Cerrahi sonras\u0131 plevral mezotelyomada nivolumab ile kemoterapi. Ann Oncol. 31 (S4), TiP1912. European Society of Medical Oncology y\u0131ll\u0131k toplant\u0131s\u0131nda poster sunumu.<\/p>\n<p>2) Christoph DC, Rizzo F, Kambartel K-O, Winke S, Panse J, Abdulla DS, Scheffler M, Azeh IT, Hoiczyk M, Turki A, Metzenmacher M (2020): \u0130mm\u00fcn kontrol noktas\u0131 inhibisyonu ba\u015far\u0131s\u0131zl\u0131\u011f\u0131 sonras\u0131 etkili bir tedavi se\u00e7ene\u011fi olarak dosetaksel\/nintedanib: ger\u00e7ek ya\u015fam kan\u0131tlar\u0131. Ann Oncol. 31 (S4), P1374. European Society of Medical Oncology y\u0131ll\u0131k toplant\u0131s\u0131nda poster sunumu.<\/p>\n<p>3) Christoph DC, Barbato F, Chodyla M-K, Fendler WP, Kessler L, Pomykala KL, Metzenmacher M, Krefting F, Hager T, Herrmann K, Ferdinandus J (2020): Malign mezotelyomada y\u00fcksek doz pembrolizumab alan hastalarda hacimsel PET yan\u0131t de\u011ferlendirmesi, konvansiyonel kriterlerden \u00fcst\u00fcnd\u00fcr. Ann Oncol. 31 (S4), MO1896. European Society of Medical Oncology y\u0131ll\u0131k toplant\u0131s\u0131nda mini s\u00f6zl\u00fc sunum.<\/p>\n<p>4) Faehling M, Schumann C, Christopoulos P, Hoffknecht P, Alt J, Horn M, Eisenmann S, Schlenska-Lange A, Aries SP, Sackmann S, Schuett P, Steger F, Christoph D (2020): Lokal ileri, rezeksiyon yap\u0131lamayan KHDAK\u2019de kesin radyokemoterapi (RKT) sonras\u0131 durvalumab: Alman geni\u015fletilmi\u015f eri\u015fim program\u0131ndan (EAP) sa\u011fkal\u0131m ve g\u00fcvenli\u011fe ili\u015fkin ger\u00e7ek ya\u015fam verileri. Ann Oncol. 31 (S4), P1244. European Society of Medical Oncology y\u0131ll\u0131k toplant\u0131s\u0131nda poster sunumu.<\/p>\n<p>5) Girard N, Fietkau R, Garassino M, Garrido P, Field JK, Peters S, Smit HJM, P\u00e9rol M, Merle P, Sibille A, Markman B, Bouchaab H, Moskovitz M, Schumann C, Gregorc V, Klein AB, Diaz Perez I, Sawyer W, Licour M, Christoph D (2020): Pacific R\u2019ye dahil edilen ilk 615 hastan\u0131n \u00f6zellikleri: Kemoradyoterapi sonras\u0131 durvalumab ile tedavi edilen, rezeksiyon yap\u0131lamayan Evre III KHDAK hastalar\u0131na ili\u015fkin ilk ger\u00e7ek ya\u015fam verilerini i\u00e7eren bir \u00e7al\u0131\u015fma. Ann Oncol. 31 (S4), P1242. European Society of Medical Oncology y\u0131ll\u0131k toplant\u0131s\u0131nda poster sunumu.<\/p>\n<p>6) Ferdinandus J, Barbato F, Chodyla M, Fendler W, Kessler L, Metzenmacher M, Krefting F, Hager T, Herrmann K, Christoph D (2020): PERCIST t\u00fcrevi metabolik hacim yan\u0131t\u0131, pembrolizumab ile tedavi edilen malign plevral mezotelyoma hastalar\u0131nda genel ve progresyonsuz sa\u011fkal\u0131m\u0131 \u00f6ng\u00f6r\u00fcr. Journal of Nuclear Medicine 61 (ek 1) 243. Society of Nuclear Medicine and Molecular Imaging 2020 y\u0131ll\u0131k toplant\u0131s\u0131nda poster sunumu.<\/p>\n<p><strong>2019<\/strong><br \/>\n1) Christoph D, Behringer D, Emde TO, Goekkurt E, Hinske C, Laack E, M\u00fcller-H\u00fcssmann H, Schlenska-Lange A, Sch\u00fctt P, Schumann C, Seese B, Fietkau R (2019): PACIFIC-R: Kemoradyoterapi sonras\u0131 durvalumab ile tedavi edilen, rezeksiyon yap\u0131lamayan Evre III KHDAK hastalar\u0131nda ilk ger\u00e7ek ya\u015fam \u00e7al\u0131\u015fmas\u0131. Oncol Res Treat 42 (Ek 4), P757. DGHO, OeGHO ve SGHSSH y\u0131ll\u0131k toplant\u0131s\u0131nda poster sunumu.<\/p>\n<p>2) Girard N, Mornex F, Christoph D, Fietkau R, Filippi A, Field J, Garrido Lopez P, McDonald F, Peters S, Klein A, Licour M, Garassino M (2019): PACIFIC-R: Kemoradyoterapi sonras\u0131 durvalumab ile tedavi edilen, rezeksiyon yap\u0131lamayan Evre III KHDAK hastalar\u0131nda ilk ger\u00e7ek ya\u015fam \u00e7al\u0131\u015fmas\u0131. TiP 101. European Lung Cancer Conference 2019\u2019da poster sunumu.<\/p>\n<p>3) Christoph DC, Gettinger, S, Beck JT, Yang X, Telivala B, Morgensztern B, Velcheti V, Ramalingam S, Schalper K, Dajee M, Ranck A, Yang R, Spigel DR (2019): CheckMate 592: Evre IV veya n\u00fcks KHDAK hastalar\u0131nda birinci basamak nivolumab (nivo) + ipilimumab (ipi) tedavisinin etkinli\u011fiyle ili\u015fkili biyobelirte\u00e7lere y\u00f6nelik Faz 2 ke\u015fif \u00e7al\u0131\u015fmas\u0131. Der Pneumologe, P618. DGP y\u0131ll\u0131k toplant\u0131s\u0131nda poster sunumu.<\/p>\n<p><strong>2018<\/strong><br \/>\n1) Staehler M, Christoph D, St\u00f6ckle M, Harde J, Stenzl A, Klein D, Benz-R\u00fcd I, Gr\u00fcnwald V (2018): Faz IV MARC-2 \u00e7al\u0131\u015fmas\u0131n\u0131n nihai sonu\u00e7lar\u0131: Metastatik renal h\u00fccreli karsinomda bir \u00f6nceki VEGFR-tirozin kinaz inhibit\u00f6r\u00fc tedavisinin ba\u015far\u0131s\u0131zl\u0131\u011f\u0131 sonras\u0131 everolimus. J Cancer Res Clin Oncol. Cilt 41 (Ek 4), P610. DGHO, OeGHO ve SGHSSH y\u0131ll\u0131k toplant\u0131s\u0131nda poster sunumu.<\/p>\n<p>2) Nadjm S, Exner JP, Gauler T, P\u00f6ttgen C, Darwiche K, Cheufou D, Krebs B, Metzenmacher M, Oezkan F, Rebmann V, Umutlu L, Deusch C, Li Y, Lahner H, Christoph D, Hoiczyk M, Witzke O, Hoffmann AC, Aigner C, Theegarten D, Taube C, Schuler M, Stamatis G, Stuschke M, Eberhardt W (2018): Akci\u011fer kanseri (AK) hastalar\u0131nda (Pts) uzun d\u00f6nem sa\u011fkal\u0131m (LTS) ve ya\u015fam\u0131n\u0131 s\u00fcrd\u00fcren hastalar program\u0131 (SS-P). Uzun d\u00f6nem toksisiteler (Tox) ve ge\u00e7 morbiditeler (Morb) \u00fczerine ara\u015ft\u0131rmalar (Invest). J Cancer Res Clin Oncol. Cilt 41 (Ek 3), P436. 33. Alman Kanser Kongresi\u2019nde poster sunumu.<\/p>\n<p>3) Mairinger F, Schmeller J, Wessolly M, Mairinger E, Borchert S, Kollmeier J, Hager T, Mairinger T, Christoph D, Walter R, Pl\u00f6nes T, Wohlschl\u00e4ger J, Jasani B, Schmid KW, Bankfalvi A (2018): \u0130mm\u00fcnohistokimyasal olarak saptanabilir metallotiyonein ekspresyonu, malign plevral mezotelyomalarda platin bazl\u0131 kemoterapinin erken ba\u015far\u0131s\u0131zl\u0131\u011f\u0131 ile g\u00fc\u00e7l\u00fc bi\u00e7imde ili\u015fkilidir. J Cancer Res Clin Oncol. Cilt 41 (Ek 3), P406. 33. Alman Kanser Kongresi\u2019nde poster sunumu.<\/p>\n<p>4) Mairinger F, Meier S, Wessolly M, K\u00f6hler C, Wagner F, Mairinger E, Schmeller J; Borchert S; Wohlschl\u00e4ger J, Pl\u00f6nes T, Hager T, Rozynek P, Kollmeier J, Christoph D, Schmid KW, Mairinger T, Johnen G, Walter R (2018): OncMass spektrometri tabanl\u0131 metilasyon analizi (MDM2, CDKN2A, RB1, TP53 ve TP73) ve malign plevral mezotelyomada MDM2 a\u015f\u0131r\u0131 ekspresyonu ile ili\u015fkiler. J Cancer Res Clin Oncol. Cilt 41 (Ek 3), P404. 33. Alman Kanser Kongresi\u2019nde poster sunumu.<\/p>\n<p>5) Mairinger FD, Schmeller J, Wessolly M, Mairinger E, Borchert S, Kollmeier J, Hager T, Christoph DC, Walter RFH, Eberhardt W, Pl\u00f6nes T, Wohlschl\u00e4ger J, Jasani B, Schmid KW, Bankfalvi A (2018): \u0130mm\u00fcnohistokimyasal olarak saptanabilir metallotiyonein ekspresyonu, malign plevral mezotelyomalarda platin bazl\u0131 kemoterapinin erken ba\u015far\u0131s\u0131zl\u0131\u011f\u0131 ile g\u00fc\u00e7l\u00fc bi\u00e7imde ili\u015fkilidir. Pathologe 39 (ek 1), AG03.P.09. DGP y\u0131ll\u0131k toplant\u0131s\u0131nda poster sunumu.<\/p>\n<p>6) S. Borchert S, Wessolly M, Schmeller J, Mairinger E, Kollmeier J, Hager T, Mairinger T, Christoph DC; Walter RF, Bankfalvi A, Eberhardt WEE, Pl\u00f6nes T, Wohlschl\u00e4ger J, Aigner C, Schmid KW, Mairinger FD (2018): Malign plevral mezotelyomada yeni tedavi stratejileri i\u00e7in potansiyel prediktif belirte\u00e7 olarak BRCAness fenotipi. Pathologe 39 (ek 1), AG03.P.08. DGP y\u0131ll\u0131k toplant\u0131s\u0131nda poster sunumu.<\/p>\n<p>7) Wessolly M, Schmeller J, Mairinger E, Borchert S, Kollmeier J, Hager T, Mairinger T, Christoph DC, Walter RFH, Eberhardt WEE, Pl\u00f6nes8 T, Wohlschl\u00e4ger J, Schmid KW, Bankfalvi A, Mairinger1 FD (2018): Malign plevral mezotelyomada miRNA d\u00fczenlemesi, DNA hasar onar\u0131m\u0131 ve tan\u0131nmas\u0131 a\u00e7\u0131s\u0131ndan \u00f6nemlidir. Pathologe 39 (ek 1), AG-O303. DGP y\u0131ll\u0131k toplant\u0131s\u0131nda s\u00f6zl\u00fc sunum.<\/p>\n<p><strong>2017<\/strong><br \/>\n1) Stratmann JA, Hornetz S, Griesinger F, Wolf J, Christoph DC, Sackmann S, Spengler W, Bischoff H, Sch\u00e4fer M, Alt J, M\u00fcller A, Laack E, Kimmich M, Sebastian M (2017): \u0130leri evre k\u00fc\u00e7\u00fck h\u00fccreli d\u0131\u015f\u0131 akci\u011fer kanseri hastalar\u0131nda osimertinib (Tagrisso) i\u00e7in geni\u015fletilmi\u015f eri\u015fim program\u0131: Almanya\u2019dan veri raporu. J Cancer Res Clin Oncol. Cilt 40 (Ek 3), P591. DGHO, OeGHO ve SGHSSH y\u0131ll\u0131k toplant\u0131s\u0131nda poster sunumu.<\/p>\n<p>2) Oezkan F, Herold T, Darwiche K, Eberhardt W, Christoph D, Worm K, Freitag L, Schmid K, Hager T, Breitenbuecher F, Schuler M (2017): Akci\u011fer adenokarsinomuna ait EBUS-TBNA \u00f6rneklerinde EGFR del ex19 ve KRAS ekzon 2 mutasyonlar\u0131n\u0131n h\u0131zl\u0131 ve y\u00fcksek duyarl\u0131l\u0131kla saptanmas\u0131. J Thorac Oncol. Cilt 11, Say\u0131 11, Ek 1. P3.02B-025. World Conference on Lung Cancer 2016\u2019da poster sunumu.<\/p>\n<p>3) Mairinger FD, Werner R, Flom E, Vollbrecht C, Schmeller J, Borchert S, Wohlschlaeger J, Mairinger T, Kollmeier J, Christoph DC, Schmid KW, Walter RFH (2017): Malign plevral mezotelyomada miRNA d\u00fczenlemesi, DNA hasar onar\u0131m\u0131 ve tan\u0131nmas\u0131 a\u00e7\u0131s\u0131ndan \u00f6nemlidir. Pathologe 38 (ek 1), P-702. DGP y\u0131ll\u0131k toplant\u0131s\u0131nda poster sunumu.<\/p>\n<p>4) Vollbrecht C, Werner R, Walter RFH, Christoph DC, Heukamp, LC, Peifer M, Hirsch B, Burbat L, Mairinger T, Schmid KW, Wohlschlaeger J, Mairinger FD (2017): Hedefe y\u00f6nelik paralel dizileme kullan\u0131larak n\u00f6roendokrin \u00f6zellikler g\u00f6steren pulmoner t\u00fcm\u00f6rlerin mutasyon analizi. Pathologe 38 (ek 1), P-0606. DGP y\u0131ll\u0131k toplant\u0131s\u0131nda poster sunumu.<\/p>\n<p>5) Garassino M, Rizvi N, Besse B, J\u00e4nne P, Christoph D, Peters S, Toh CK, Kurata T, Costa EC, Koczywas M, Felip E, Chaft J, Qiu J, Kowanetz M, Coleman S, Mocci S, Sandler A, Gettinger S, Johnson M (2017): PD-L1 se\u00e7ilmi\u015f hastalarda ileri KHDAK i\u00e7in 1. basamak tedavi olarak atezolizumab: BIRCH \u00e7al\u0131\u015fmas\u0131ndan g\u00fcncellenmi\u015f ORR, PFS ve OS verileri. J Thorac Oncol. Cilt 12 Say\u0131 1, Ek 1. OA03.02. World Conference on Lung Cancer 2016\u2019da s\u00f6zl\u00fc sunum.<\/p>\n<p><strong>2016<\/strong><br \/>\n1) Wakelee H, Patel JD, Heist R, Balmanoukian A, Besse B, Felip E, Costa EC, Chow LQ, Koczywas M, Garassino MC, Christoph D, Toh CK, Johnson ML, Chaft J, Kurata T, Qiu J, Kowanetz M, Coleman S, Mocci S, Sandler A, Gettinger SN, Peters S (2016): PD-L1 se\u00e7ilmi\u015f ileri KHDAK hastalar\u0131nda atezolizumab i\u00e7in Faz II \u00e7al\u0131\u015fma (BIRCH): G\u00fcncellenmi\u015f etkinlik ve ke\u015fif ama\u00e7l\u0131 biyobelirte\u00e7 sonu\u00e7lar\u0131. J Thorac Oncol. Cilt 11, Say\u0131 11, Ek 1. ORAL01.04. \u201cChicago Multidisciplinary Symposium in Thoracic Oncology\u201d 2016\u2019da s\u00f6zl\u00fc sunum.<\/p>\n<p><strong>2015<\/strong><br \/>\n1) Walter RFH, Vollbrecht C, Christoph DC, Werner R, Mairinger T, Theegarten D, Schmid KW, Wohlschlaeger J, Mairinger FD (2015): Masif paralel dizileme ve dijital gen ekspresyon analizi ile pulmoner n\u00f6roendokrin t\u00fcm\u00f6rlerde farmas\u00f6tik hedeflerin ara\u015ft\u0131r\u0131lmas\u0131. Pathologe 36 (ek 1), SO-069. DGP y\u0131ll\u0131k toplant\u0131s\u0131nda poster sunumu.<\/p>\n<p>2) Walter RFH, Werner R, Vollbrecht C, Theegarten D, Worm K, Mairinger T, Wohlschlaeger J, Christoph DC, Mairinger FD (2015): Nutlin-3A\u2019n\u0131n kilit oyuncular\u0131, MDM2-pozitif ve -negatif plevral mezotelyomalar aras\u0131nda miRNA\u2019lar arac\u0131l\u0131\u011f\u0131yla farkl\u0131 \u015fekilde d\u00fczenlenmektedir. Pathologe 36 (ek 1), SO-018. DGP y\u0131ll\u0131k toplant\u0131s\u0131nda poster sunumu.<\/p>\n<p>3) Walter RFH, Mairinger F, Werner R, Vollbrecht C, Mairinger T, Worm K, Schmid KW, Christoph DC, Wohlschl\u00e4ger J (2015): Malign plevral mezotelyoman\u0131n molek\u00fcler biyolojik analizi. Pathologe 36 (ek 1), SO-071. DGP y\u0131ll\u0131k toplant\u0131s\u0131nda poster sunumu.<\/p>\n<p><strong>2014<\/strong><br \/>\n1) Walter RFH, Mairinger FD, Werner R, Ting S, Vollbrecht C, Theegarten D, Stamatis G, Zwanziger D, Eberhardt W, Schuler M, Christoph DC, Freitag L, Schmid KW &#038; Wohlschlaeger J (2014): NanoString teknolojisi kullan\u0131larak 80 n\u00f6roendokrin akci\u011fer kanseri hastas\u0131n\u0131n taranmas\u0131, yeni ki\u015fiye \u00f6zel tedaviler i\u00e7in \u00e7e\u015fitli hedefleri ortaya koymaktad\u0131r. Pathologe 35 (ek 1), SA-096. DGP y\u0131ll\u0131k toplant\u0131s\u0131nda poster sunumu.<\/p>\n<p>2) Walter RFH, Mairinger FD, Ting S, Vollbrecht C, Hager T, Worm K, Eberhardt W, Kollmeier J, Mairinger T, Christoph DC, Schmid KW, Freitag L &#038; Wohlschlaeger J (2014): Nutlin-3 ile MDM2\u2019nin inhibisyonu\u2014k\u00f6t\u00fc prognozlu plevral mezotelyomada bir sonraki tedavi mi? Pathologe 35 (ek 1), SA-095. DGP y\u0131ll\u0131k toplant\u0131s\u0131nda poster sunumu.<\/p>\n<p>3) Mairinger F, Ting S, Werner R, Walter RFH, Hager T, Vollbrecht C, Christoph D, Worm K, Mairinger T, Sheu-Grabellus S-Y, Theegarten D, Schmid KW &#038; Wohlschlaeger J (2014): Farkl\u0131 mikro-RNA ekspresyon profilleri, akci\u011ferin n\u00f6roendokrin t\u00fcm\u00f6rlerinin alt tiplerini ay\u0131rt eder: bir profilleme \u00e7al\u0131\u015fmas\u0131n\u0131n sonu\u00e7lar\u0131. Pathologe 35 (ek 1), SA-080. DGP y\u0131ll\u0131k toplant\u0131s\u0131nda poster sunumu.<\/p>\n<p>4) Walter RFH, Mairinger FD, Werner R, Ting S, Vollbrecht C, Theegarten D, Stamatis G, Zwanziger D, Eberhardt W, Schuler M, Christoph DC, Freitag L, Schmid KW &#038; Wohlschlaeger J (2014): Apoptoz ve h\u00fccre d\u00f6ng\u00fcs\u00fc ile ili\u015fkili genlerin mRNA ekspresyon profili, akci\u011ferin n\u00f6roendokrin t\u00fcm\u00f6rlerinde agresifli\u011fin bir belirteci midir? Pathologe 35 (ek 1), FR-048. DGP y\u0131ll\u0131k toplant\u0131s\u0131nda poster sunumu.<\/p>\n<p>5) Mairinger F, Walter FRH, Werner R, Vollbrecht C, Ting S, Hager T, Schmid KW, Wohlschlaeger J &#038; Christoph D (2014): Pulmoner n\u00f6roendokrin t\u00fcm\u00f6rlerde folik asit metabolizmas\u0131 ve DNA uyumsuzluk onar\u0131m\u0131: potansiyel kemoterapi diren\u00e7 mekanizmalar\u0131n\u0131n belirlenmesi. Pathologe 35 (ek 1), FR-044. DGP y\u0131ll\u0131k toplant\u0131s\u0131nda poster sunumu.<\/p>\n<p>6) Mairinger F, Walter RFH, Werner R, Ting T, Hager T, Vollbrecht C, Theegarten D, Christoph D, Schmid KW &#038; Wohlschlaeger J (2014): Anjiyogenezin aktivasyonu, pulmoner karsinoidler ile n\u00f6roendokrin karsinomlar aras\u0131nda belirgin bi\u00e7imde farkl\u0131d\u0131r ve karsinoid t\u00fcm\u00f6r olu\u015fumu i\u00e7in kritiktir. Pathologe 35 (ek 1), FR-043. DGP y\u0131ll\u0131k toplant\u0131s\u0131nda poster sunumu.<\/p>\n<p><strong>2013<\/strong><br \/>\n1) Mairinger F, Ting S, Vollbrecht C, Walter RFH, Kollmeier J, Grief S, Hager T, Mairinger T, Christoph D, Schmid KW &#038; Wohlschl\u00e4ger J (2013): P53 E3 ubikuitin protein ligaz homologu (fare) (MDM-2) imm\u00fcnoekspresyonu, malign plevral mezotelyomada k\u00f6t\u00fc genel sa\u011fkal\u0131m\u0131n g\u00fc\u00e7l\u00fc bir \u00f6ng\u00f6r\u00fcc\u00fcs\u00fcd\u00fcr. Pathologe 34 (ek 1), FR-103. DGP y\u0131ll\u0131k toplant\u0131s\u0131nda poster sunumu.<\/p>\n<p>2) Mairinger F, Ting S, Worm K, Hager T, Wohlschl\u00e4ger J, Schmid KW &#038; Christoph D (2013): LH1, MSH2, MSH6 ve ERCC1: MPM\u2019de platin bazl\u0131 kemoterapiye yan\u0131tla ili\u015fkili DNA uyumsuzluk onar\u0131m proteinleri mi? Pathologe 34 (ek 1), FR-078. DGP y\u0131ll\u0131k toplant\u0131s\u0131nda poster sunumu.<\/p>\n<p>3) Mairinger F, Walter RFH, Hager T, Vollbrecht C, Christoph D, Worm K, Ting S, Schmid KW &#038; Wohlschl\u00e4ger J (2013): Proteazom alt birimleri PSMA5 ve PSMB4, akci\u011ferin tipik ve atipik karsinoid t\u00fcm\u00f6rlerini ay\u0131rt etmek i\u00e7in g\u00fc\u00e7l\u00fc belirte\u00e7lerdir. Pathologe 34 (ek 1), DO-036. DGP y\u0131ll\u0131k toplant\u0131s\u0131nda s\u00f6zl\u00fc sunum.<\/p>\n<p><strong>2012<\/strong><br \/>\n1)Christoph DC, Reyna Asuncion B, Hassan B, Maltzman J, O\u2019Shannessy D, Gauler TC, Wohlschlaeger J, Wynes MW, Schuler M, Eberhardt WEE &#038; Hirsch FR (2012): Pemetreksed bazl\u0131 kemoterapi ile tedavi edilen metastatik K\u00fc\u00e7\u00fck H\u00fccreli D\u0131\u015f\u0131 Akci\u011fer Kanseri hastalar\u0131nda Folat Resept\u00f6r\u00fc alfa (FRA) ve Timidilat Sentaz (TS) ekspresyonunun \u00f6nemi. Onkologie 36 (ek 6; \u00f6zet V125). DGHO, OeGHO ve SGHSSH y\u0131ll\u0131k toplant\u0131s\u0131nda sunum.<\/p>\n<p>2)Christoph DC, Reyna Asuncion B, Hassan B, Maltzman J, O\u2019Shannessy D, Gauler TC, Wynes MW, Schuler M, Eberhardt WEE &#038; Hirsch FR (2012): Pemetreksed bazl\u0131 kemoterapi ile tedavi edilen metastatik K\u00fc\u00e7\u00fck H\u00fccreli D\u0131\u015f\u0131 Akci\u011fer Kanseri hastalar\u0131nda Folat Resept\u00f6r\u00fc alfa ve Timidilat Sentaz proteinlerinin ekspresyonunun incelenmesi. J Thorac Oncol 10 (Ek 2). \u201cChicago Multidisciplinary Symposium in Thoracic Oncology\u201d 2012\u2019de sunum.<\/p>\n<p>3)Christoph DC, Reyna Asuncion B, Wynes MW, Gauler TC, Wohlschlaeger J, Theegarten D, Welter S, Tran C, Hassan B, Loewendick H, Peglow A, Schuler M, Eberhardt WEE &#038; Hirsch FR (2012): Folilpol\u0131-\u03b3-glutamat sentetaz ve timidilat sentaz, ileri evre k\u00fc\u00e7\u00fck h\u00fccreli d\u0131\u015f\u0131 akci\u011fer kanserinde (KHDAK\/NSCLC) pemetreksed bazl\u0131 tedavinin klinik sonu\u00e7lar\u0131yla ili\u015fkilidir. \u00d6zet 1713. American Association of Cancer Research y\u0131ll\u0131k toplant\u0131s\u0131nda poster sunumu.<\/p>\n<p>4)Christoph DC, Reyna Asuncion B, Wynes MW, Gauler TC, Wohlschlaeger J, Theegarten D, Welter S, Tran C, Hassan B, Loewendick H, Peglow A, Schuler M, Eberhardt WEE &#038; Hirsch FR (2012): Folilpol\u0131-glutamat sentetaz ve timidilat sentaz, ileri evre k\u00fc\u00e7\u00fck h\u00fccreli d\u0131\u015f\u0131 akci\u011fer kanserinde (KHDAK\/NSCLC) pemetreksed bazl\u0131 tedavinin klinik sonu\u00e7lar\u0131yla ili\u015fkilidir. Poster B6. AACR-IASLC Ortak Konferans\u0131 \u201cMolecular Origins of Lung Cancer: Biology, Therapy, and Personalized Medicine\u201d, San Diego, CA, ABD\u2019de poster sunumu.<\/p>\n<p><strong>2011<\/strong><br \/>\n1)Christoph DC, Kasper S, Gauler TC, Breitenbuecher F, Engelhard M, Theegarten D, Poettgen C, Hepp R, Peglow A, Loewendick H, Schuler M, Hirsch FR, Eberhardt WEE &#038; Wohlschlaeger J (2011): K\u00fc\u00e7\u00fck h\u00fccreli d\u0131\u015f\u0131 akci\u011fer kanserinde taksanlarla tedaviden klinik fayday\u0131 \u00f6ng\u00f6ren yeni bir biyobelirte\u00e7 olarak betaV-t\u00fcb\u00fclin ekspresyonunun de\u011ferlendirilmesi. Eur J Cancer 47 (ek 4; \u00f6zet PP35). EORTC-NCI-ASCO \u201cMolecular Markers in Cancer\u201d y\u0131ll\u0131k toplant\u0131s\u0131nda poster sunumu.<\/p>\n<p>2)Gauler TC, Poettgen C, Korfee S, Wagner H, Hepp R, Stamatis G, Christoph DC, Passlick B, Budach V, Seeber S, Wilke H, Stuschke M &#038; Eberhardt W (2011): Operabl IIIA KHDAK\u2019da, ind\u00fcksiyon (IND) kemoterapisi (CTx) ard\u0131ndan e\u015fzamanl\u0131 (cc) kemoradyoterapi (CTx\/RTx) + cerrahi (S) (=TR\u0130MODAL\u0130TE) ve buna ek olarak PCI ile, yaln\u0131zca lokal tedavinin (S + RTx) kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131\u011f\u0131 prospektif \u00e7ok merkezli Alman randomize \u00e7al\u0131\u015fmas\u0131nda uzun d\u00f6nem sa\u011fkal\u0131m (LTS) ve rekabet eden riskler. J Thorac Oncol. 6 (ek 2; \u00f6zet 2575). World Conference on Lung Cancer 2011\u2019de mini sunum.<\/p>\n<p>3)Poettgen C, Le Pechoux C, Gauler TC, Stuschke M, Grunenwald DH, Stamatis G, Bildat S, Krbek T, Christoph DC, Welter S, Fischer B, Hepp R, Theegarten D &#038; Eberhardt W (2011): \u00dc\u00e7 k\u00fcr sisplatin(P)\/paklitaksel(T) ile ind\u00fcksiyon (IND) kemoterapisi (CTx) ard\u0131ndan e\u015fzamanl\u0131 (cc) kemoradyoterapi (CTx\/RTx) P\/etoposid (eto)\/45 Gy (g\u00fcnde 2 kez 1,5 Gy) + cerrahi (S) \u2013 \u00e7ok merkezli faz II \u00e7al\u0131\u015fma (CISTAXOL) kapsam\u0131nda 10 y\u0131ll\u0131k uzun d\u00f6nem sa\u011fkal\u0131m (LTS). J Thorac Oncol. 6 (ek 2; \u00f6zet 2.563). World Conference on Lung Cancer 2011\u2019de mini sunum.<\/p>\n<p>4)Christoph DC, Mascaux C, Wynes MW, Reyna Asuncion B, Wohlschlaeger J, Theegarten D, Gauler TC, Neumann V, Poettgen C, Tran C, Tannapfel A, Schuler M, Eberhardt WEE &#038; Hirsch FR (2011): Malign plevral mezotelyomada pemetreksedden klinik fayday\u0131 \u00f6ng\u00f6rmede timidilat sentaz ve folilpol\u0131-glutamat sentetaz\u0131n prediktif de\u011feri. J Thorac Oncol. 6 (ek 2; \u00f6zet 2.480). World Conference on Lung Cancer 2011\u2019de poster sunumu.<\/p>\n<p>5)Eberhardt W, Hepp R, Gauler TC, Christoph DC, Hoffmann A-C, Theegarten D, Welter S, Schmid KW, Wohlschlaeger J, Passlick B, Le P\u00e9choux C, Stamatis G, Stuschke M &#038; Poettgen C (2011): Ard\u0131\u015f\u0131k trimodalite (TM) \u00e7al\u0131\u015fmalar\u0131nda tedavi edilen lokal ileri (LAD) evre III k\u00fc\u00e7\u00fck h\u00fccreli d\u0131\u015f\u0131 akci\u011fer kanseri (KHDAK\/NSCLC) hastalar\u0131nda (pts) rekabet eden riskler analizi ve uzun d\u00f6nem sa\u011fkal\u0131m (LTS). J Thorac Oncol 6: 2011 (ek 2; \u00f6zet 2.200). World Conference on Lung Cancer 2011\u2019de sunum.<\/p>\n<p>6)Christoph DC, Wohlschlaeger J, Neumann V, Gauler TC, Poettgen C, Peglow A, Tannapfel A, Schuler M, Hirsch FR, Eberhardt WEE &#038; Theegarten D (2011): Malign plevral mezotelyomada pemetreksedden klinik fayda a\u00e7\u0131s\u0131ndan dihidrofolat red\u00fcktaz ekspresyonunun etkisi. J Thorac Oncol. 6 (ek 2; \u00f6zet 1.853). World Conference on Lung Cancer 2011\u2019de poster sunumu.<\/p>\n<p>7)Christoph DC, Kasper S, Gauler TC, Breitenbuecher F, Engelhard M, Theegarten D, Poettgen C, Hepp R, Peglow A, Loewendick H, Schuler M, Hirsch FR, Eberhardt WEE &#038; Wohlschlaeger J (2011): K\u00fc\u00e7\u00fck h\u00fccreli d\u0131\u015f\u0131 akci\u011fer kanserinde taksanlarla tedaviden klinik fayday\u0131 \u00f6ng\u00f6ren yeni bir biyobelirte\u00e7 olarak betaV-t\u00fcb\u00fclin ekspresyonunun de\u011ferlendirilmesi. J Thorac Oncol. 6 (ek 2; \u00f6zet 2.227). World Conference on Lung Cancer 2011\u2019de poster sunumu.<\/p>\n<p>8)Christoph DC, Mascaux C, Wynes MW, Reyna Asuncion B, Wohlschlaeger J, Theegarten D, Gauler TC, Schuler M, Eberhardt WEE &#038; Hirsch FR (2011): Malign plevral mezotelyomada pemetreksedden klinik fayday\u0131 \u00f6ng\u00f6rmede timidilat sentaz ve folilpol\u0131-glutamat sentetaz\u0131n prediktif de\u011feri. J Clin Oncol. 29 (ek; \u00f6zet 7024). American Society of Clinical Oncology y\u0131ll\u0131k toplant\u0131s\u0131nda poster tart\u0131\u015fmas\u0131.<\/p>\n<p>9) Christoph DC, Wittkowski L, Stattaus J, P\u00f6ttgen C, Keyvani K, Gauler TC, Schuler M &#038; Eberhardt WEE (2011): Demans olarak ortaya \u00e7\u0131kan bir pulmoner adenokarsinomun \u00e7ok ge\u00e7 ve izole leptomeningeal n\u00fcks\u00fc. Onkologie 34 (ek 6; \u00f6zet P574). DGHO, OeGHO ve SGHSSH y\u0131ll\u0131k toplant\u0131s\u0131nda poster sunumu.<\/p>\n<p><strong>2009<\/strong><br \/>\n1) Gauler TC, Christoph DC, Gamarra F, Fuhr H-G, Gonschorek C, Giurescu M, Frickhofen N, Huber RM, Schuler M &#038; Eberhardt WEE (2008): Kemoterapi almam\u0131\u015f yayg\u0131n hastal\u0131kl\u0131 k\u00fc\u00e7\u00fck h\u00fccreli akci\u011fer kanseri (ED-SCLC) olan hastalarda sagopilonun (ZK-EPO) sisplatin ile kombinasyonunun Faz I \u00e7al\u0131\u015fmas\u0131. Ann Oncol. 19 (ek 1: \u00f6zet 331P). European Cancer Organisation\/European Society of Medical Oncology y\u0131ll\u0131k toplant\u0131s\u0131nda poster sunumu.<\/p>\n<p>2) Christoph DC, Gauler TC, Gamarra F, Fuhr H-G, Fischer JR, Gonschorek C, Frickhofen N, Huber RM, Schuler M &#038; Eberhardt WEE (2009): Yayg\u0131n hastal\u0131kl\u0131 k\u00fc\u00e7\u00fck h\u00fccreli akci\u011fer kanseri (ED-SCLC) olan hastalarda 1. basamak tedavi olarak sagopilonun sisplatin ile kombinasyonunun Faz I denemesi. Eur J Cancer Suppl. 7 (\u00f6zet Po9142). European Cancer Organisation\/European Society OF Medical Oncology y\u0131ll\u0131k toplant\u0131s\u0131nda poster sunumu.<\/p>\n<p>3) Gauler TC, Christoph DC, Gamarra F, Fuhr H-G, Fischer JR, Gonschorek C, Giurescu M, Frickhofen N, Huber RM, Schuler M &#038; Eberhardt WEE (2009): Kemoterapi almam\u0131\u015f yayg\u0131n hastal\u0131kl\u0131 k\u00fc\u00e7\u00fck h\u00fccreli akci\u011fer kanseri (ED-SCLC) olan hastalarda sagopilonun (ZK-EPO) sisplatin ile kombinasyonunun Faz I \u00e7al\u0131\u015fmas\u0131. J Thorac Oncol. 4 (ek 1; \u00f6zet PD4.4.1). World Conference on Lung Cancer 2009\u2019da poster tart\u0131\u015fmas\u0131.<\/p>\n<p><strong>2008<\/strong><br \/>\n1) Christoph DC, Gauler TC, Gamarra F, Fuhr H-G, Gonschorek C, Giurescu M, Frickhofen N, Huber RM, Schuler M &#038; Eberhardt WEE (2008): Yayg\u0131n hastal\u0131kl\u0131 k\u00fc\u00e7\u00fck h\u00fccreli akci\u011fer kanseri (ED-SCLC) olan hastalarda birinci basamak tedavi olarak sagopilonun (ZK-EPO) sisplatin ile kombinasyonunun Faz I denemesi. Onkologie 31 (ek 4; \u00f6zet V180). DGHO, OeGHO ve SGHSSH y\u0131ll\u0131k toplant\u0131s\u0131nda sunum.<\/p>\n<p><strong>2004<\/strong><br \/>\n1) Schmidt M, Stope MB, Szatkowski DC, vom Dorp F, Oude Weernink PA &#038; Jakobs KH (2004): Gs ile e\u015fle\u015fmi\u015f resept\u00f6rler arac\u0131l\u0131\u011f\u0131yla Epac ve Ca2+ kontroll\u00fc Ras ve ekstrasel\u00fcler sinyal d\u00fczenleyici kinazlar\u0131n aktivasyonu. N-S Arch Pharmacol. 371 (ek 1; \u00f6zet R10). DGPT 2003 y\u0131ll\u0131k toplant\u0131s\u0131nda sunum.<\/p>\n<p>2) Szatkowski DC, Keiper M, Stope MB, Oude Weernink PA, Jakobs KH &#038; Schmidt M (2004): \u03b22-adrenosept\u00f6r arac\u0131l\u0131\u011f\u0131yla PLC-\u03b5 ve CalDAG2 arac\u0131l\u0131 Ras ve MAP kinaz aktivasyonu. N-S Arch Pharmacol. 369 (ek 1; \u00f6zet R203). DGPT y\u0131ll\u0131k toplant\u0131s\u0131nda sunum.<\/p>\n<p><strong>2003<\/strong><br \/>\n1) Szatkowski DC, B\u00f6hm A &#038; Schmidt M (2003): EGF arac\u0131l\u0131\u011f\u0131yla CalDAG3 ve Rap2B\u2019ye ba\u011f\u0131ml\u0131 fosfolipaz C-\u03b5 uyar\u0131m\u0131n\u0131n molek\u00fcler mekanizmalar\u0131. Essen \u00dcniversite Hastanesi 2. Ara\u015ft\u0131rma G\u00fcn\u00fc\u2019nde poster sunumu (11-18-2003).<\/p>\n<p>2) Schmidt M, Keiper M, B\u00f6hm A, Evellin S, Sari A, Szatkowski DC, vom Dorp F, OudeWeernink, PA &#038; Jakobs KH (2003): Epidermal b\u00fcy\u00fcme fakt\u00f6r\u00fc resept\u00f6r\u00fc arac\u0131l\u0131\u011f\u0131yla CalDAG3 ve Rap2B arac\u0131l\u0131 fosfolipaz C uyar\u0131m\u0131n\u0131n mekanizmalar\u0131. N-S Arch Pharmacol. 367 (ek 1; \u00f6zet R195). DGPT y\u0131ll\u0131k toplant\u0131s\u0131nda sunum.<\/p>\n<\/div><\/div><\/div><\/section>\n<section class='av_toggle_section av-m194jok1-d20761bf42ed131b77fbb631a8ac9a78'  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/CreativeWork\" ><div role=\"tablist\" class=\"single_toggle\" data-tags=\"{T\u00fcm\u00fc} \"  ><p id='toggle-toggle-id-2' data-fake-id='#toggle-id-2' class='toggler  av-title-above '  itemprop=\"headline\"  role='tab' tabindex='0' aria-controls='toggle-id-2' data-slide-speed=\"200\" data-title=\"Kitap b\u00f6l\u00fcmleri\" data-title-open=\"\" data-aria_collapsed=\"Click to expand: Kitap b\u00f6l\u00fcmleri\" data-aria_expanded=\"Click to collapse: Kitap b\u00f6l\u00fcmleri\">Kitap b\u00f6l\u00fcmleri<span class=\"toggle_icon\"><span class=\"vert_icon\"><\/span><span class=\"hor_icon\"><\/span><\/span><\/p><div id='toggle-id-2' aria-labelledby='toggle-toggle-id-2' role='region' class='toggle_wrap  av-title-above'  ><div class='toggle_content invers-color '  itemprop=\"text\" ><p><strong>2016<\/strong><br \/>\n1) Christoph DC &#038; Eberhardt WEE: Ya\u015fl\u0131 kanser hastas\u0131nda radyoterapi (B\u00f6l\u00fcm 6). \u0130\u00e7inde: Schrijvers D, Aapro M, Zakotnik B, Audisio R, van Halteren H, Hurria A. EUROPEAN SOCIETY OF MEDICAL ONCOLOGY HANDBOOK OF CANCER IN THE SENIOR PATIENT (2016). Informa Healthcare New York \u2013 London.<\/p>\n<p><strong>2012<\/strong><br \/>\n1) Eberhardt WEE, Krbek T, Theegarten D &#038; Christoph DC: Malign mezotelyoma (B\u00f6l\u00fcm 19). \u0130\u00e7inde: Meyer J, Fleig WE, Pletz MW, Mayet W-J, Mertens P, M\u00fcller O-A, Pfeifer M, Weiss N &#038; Busse O. Rationelle Diagnostik und Therapie in der Inneren Medizin. Teslimat 35 Elsevier M\u00fcnih.<\/p>\n<p><strong>2010<br \/>\n<\/strong>1) Christoph DC &#038; Eberhardt WEE: Ya\u015fl\u0131 kanser hastas\u0131nda radyoterapi (B\u00f6l\u00fcm 6). \u0130\u00e7inde: Schrijvers D, Aapro M, Zakotnik B, Audisio R, van Halteren H, Hurria A. EUROPEAN SOCIETY OF MEDICAL ONCOLOGY HANDBOOK OF CANCER IN THE SENIOR PATIENT (2010). Informa Healthcare New York \u2013 London.<\/p>\n<p><strong>2007<\/strong><br \/>\n1) Christoph D &#038; Christoph S. Sa\u011fl\u0131k sorunlar\u0131 \u2013 \u00dcriner sistem (B\u00f6l\u00fcm 10). \u0130\u00e7inde: Schaps K-P, Kessler O, Fetzner U. DAS ZWEITE \u2013 KOMPAKT (2007). Springer Heidelberg.<\/p>\n<p>2) Szatkowski D &#038; Schaps K-P. \u0130\u00e7 hastal\u0131klar\u0131 \u2013 Hematoloji, hemostaziyoloji ve dahili onkoloji (B\u00f6l\u00fcm 7). \u0130\u00e7inde: Schaps K-P, Kessler O &#038; Fetzner U. DAS ZWEITE \u2013 KOMPAKT (2007). Springer Heidelberg.<\/p>\n<\/div><\/div><\/div><\/section>\n<\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":4,"featured_media":0,"parent":4769,"menu_order":172,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-5034","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/thoraxzentrum-ruhrgebiet.de\/tr\/wp-json\/wp\/v2\/pages\/5034","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thoraxzentrum-ruhrgebiet.de\/tr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/thoraxzentrum-ruhrgebiet.de\/tr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/thoraxzentrum-ruhrgebiet.de\/tr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/thoraxzentrum-ruhrgebiet.de\/tr\/wp-json\/wp\/v2\/comments?post=5034"}],"version-history":[{"count":3,"href":"https:\/\/thoraxzentrum-ruhrgebiet.de\/tr\/wp-json\/wp\/v2\/pages\/5034\/revisions"}],"predecessor-version":[{"id":5037,"href":"https:\/\/thoraxzentrum-ruhrgebiet.de\/tr\/wp-json\/wp\/v2\/pages\/5034\/revisions\/5037"}],"up":[{"embeddable":true,"href":"https:\/\/thoraxzentrum-ruhrgebiet.de\/tr\/wp-json\/wp\/v2\/pages\/4769"}],"wp:attachment":[{"href":"https:\/\/thoraxzentrum-ruhrgebiet.de\/tr\/wp-json\/wp\/v2\/media?parent=5034"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}